haematolog
disord
common
lowincom
countri
make
substanti
contribut
morbid
mortal
individu
region
neg
impact
growth
develop
underresourc
nation
genet
red
cell
abnorm
common
lowincom
countri
provid
protect
malaria
often
coexist
caus
anaemia
malnutrit
chronic
ill
close
associ
haematolog
abnorm
infect
major
caus
ill
death
popul
morpholog
abnorm
blood
often
provid
clue
underli
diagnosi
blood
film
examin
particularli
import
diagnost
facil
limit
abnorm
blood
count
manifest
variou
combin
alter
number
red
cell
white
cell
platelet
section
outlin
common
caus
abnorm
blood
count
like
encount
clinic
practic
lowincom
countri
anaemia
one
common
caus
morbid
world
impact
reflect
sever
healthrel
millennium
develop
goal
although
anaemia
diagnosi
suggest
underli
diseas
state
need
recogn
treat
also
use
indic
gener
health
popul
caus
anaemia
may
identifi
systemat
consid
life
cycl
red
cell
figur
nutrient
necessari
red
cell
product
absorb
gastrointestin
tract
carri
portal
vein
liver
ultim
reach
bone
marrow
erythropoiesi
occur
process
regul
erythropoietin
hormon
releas
kidney
mainli
respons
hypoxia
matur
africa
asia
world
anaem
popul
anaemia
burden
highest
among
children
women
reproduct
age
accur
diagnosi
anaemia
neglect
clinic
assess
anaemia
unreli
unless
anaemia
sever
lowincom
countri
anaemia
individu
often
due
multipl
interdepend
factor
remov
treat
singl
factor
may
resolv
anaemia
earli
diagnosi
sickl
cell
diseas
rapid
access
specialist
centr
emerg
sever
pain
crise
stroke
acut
chest
syndrom
help
prevent
perman
longterm
complic
betathalassaemia
major
fatal
first
year
life
unless
regular
blood
transfus
given
unless
accompani
iron
chelat
transfus
eventu
caus
death
due
irrevers
organ
damag
iron
overload
malari
anaemia
particular
problem
children
pregnant
women
sever
anaemia
caus
p
falciparum
p
vivax
malari
anaemia
reduc
chemoprophylaxi
intermitt
treatment
antimosquito
measur
insecticidetr
bed
net
vector
control
anaemia
occur
hivinfect
patient
independ
risk
factor
death
prompt
treatment
factor
associ
anaemia
infect
poor
nutrit
commenc
antiretrovir
treatment
reduc
death
blood
shortag
common
tropic
countri
increas
avail
blood
transfus
prescrib
accord
guidelin
effort
made
encourag
blood
donor
donat
regularli
repeat
donor
safest
type
donor
reaction
character
circul
myelocyt
metamyelocyt
mistaken
leukaemia
unlik
leukaemia
orderli
matur
prolifer
neutrophil
leukaemoid
reaction
also
describ
patient
tuberculosi
juvenil
rheumatoid
arthriti
dermat
herpetiformi
decreas
margin
neutrophil
egress
cell
circul
occur
exercis
adrenalin
epinephrin
inject
emot
stress
postop
respons
drug
eg
steroid
drug
lithium
tetracyclin
produc
neutrophilia
increas
product
neutrophilia
also
featur
bone
marrow
prolifer
occur
myeloprolif
neoplasm
particularli
chronic
myeloid
leukemia
myelofibrosi
teardrop
cell
nucleat
red
blood
cell
featur
myelofibrosi
blood
film
basophilia
eosinophilia
common
chronic
myeloid
leukaemia
molecular
test
mutat
bcrabl
fusion
gene
also
help
differenti
myeloprolif
neoplasm
rebound
neutrophilia
occur
follow
treatment
megaloblast
anaemia
recoveri
neutropenia
induc
drug
acut
haemorrhag
caus
neutrophilia
especi
bleed
occur
periton
caviti
pleural
space
joint
adjac
dura
possibl
due
releas
adrenalin
chemokin
respons
local
inflamm
presenc
neutrophilia
use
rais
suspicion
onset
complic
infect
primarili
associ
neutrophilia
exampl
includ
mening
tuberculosi
orchiti
mump
bowel
perfor
typhoid
fever
superad
bacteri
infect
measl
absenc
neutrophilia
help
differenti
typhoid
paratyphoid
fever
pyogen
infect
neutropenia
defin
absolut
neutrophil
count
l
usual
classifi
sever
l
moder
red
cell
releas
circul
bone
marrow
percol
tissu
organ
anaemia
result
defect
stage
inadequ
product
red
cell
bone
marrow
due
lack
nutrient
eg
iron
b
folat
vitamin
copper
zinc
abnorm
haemoglobin
synthesi
ie
haemoglobinopathi
ineffect
erythropoeisi
myelodysplasia
infect
red
cell
lost
bodi
eg
gastrointestin
bleed
remov
prematur
abnorm
spleen
enlarg
ie
haemolysi
kidney
diseas
result
decreas
erythropoietin
anaemia
chronic
diseas
anaemia
inflamm
due
inadequ
respons
erythropoieitin
increas
cytokineinduc
hepcidin
releas
inflammatori
state
interfer
iron
absorpt
iron
util
diagnost
algorithm
determin
caus
anaemia
usual
base
combin
mean
cell
volum
red
cell
reticulocyt
count
blood
film
appear
figur
approach
base
avail
haematolog
analys
experienc
microscopist
sever
condit
caus
anaemia
may
coexist
individu
eg
intestin
parasit
malaria
sickl
cell
diseas
henc
thorough
investig
crucial
identifi
potenti
caus
anaemia
neutrophil
releas
marrow
matur
either
enter
circul
pool
remain
margin
pool
loos
attach
blood
vessel
wall
cell
margin
pool
sampl
blood
taken
full
blood
count
neutrophilia
therefor
result
increas
bone
marrow
synthesi
also
decreas
margin
increas
circul
pool
mani
caus
neutrophilia
box
commonest
bacteri
infect
increas
bone
marrow
product
neutrophil
releas
neutrophil
precursor
peripher
blood
leukaemoid
l
mild
l
propens
develop
infect
relat
degre
durat
neutropenia
higher
risk
associ
count
l
african
african
american
yemenit
jew
palestinian
saudi
arabian
gener
slightli
lower
neutrophil
count
compar
race
thought
due
increas
bone
marrow
storag
pool
ethnic
neutropenia
associ
good
neutrophil
respons
infect
neutropenia
due
impair
ineffect
intramedullari
death
neutrophil
precursor
despit
normal
bone
marrow
product
synthesi
bone
marrow
eg
myelodysplasia
megaloblast
anaemia
treatment
phenytoin
methotrex
shift
circul
pool
margin
pool
pseudoneutropenia
increas
peripher
destruct
eg
secondari
antibodi
neutrophil
increas
reticuloendotheli
activ
sepsi
haemophagocyt
syndrom
box
increas
consumpt
neutrophil
result
increas
attach
cell
endothelium
leukocyt
inflammatori
state
neutropenia
often
result
combin
sever
mechan
infant
hypertens
mother
may
moder
sever
neutropenia
last
sever
day
probabl
relat
bone
marrow
suppress
moder
sever
neutropenia
also
occur
newborn
infant
result
transfer
matern
igg
antineutrophil
antibodi
manner
similar
rhesu
haemolyt
diseas
newborn
although
neutropenia
describ
typhoid
fever
minimum
neutrophil
count
seldom
fall
l
box
neutropenia
may
develop
first
week
ill
infecti
hepat
yellow
fever
caus
neutropenia
overwhelm
infect
lead
failur
bone
marrow
product
neutrophil
especi
undernourish
individu
alcohol
individu
sever
neutropenia
develop
lifethreaten
septicaemia
often
endogen
flora
eg
oral
caviti
stringent
measur
taken
avoid
situat
may
predispos
individu
infect
may
need
prophylact
antimicrobi
rapid
access
medic
care
fungal
infect
less
common
bacteri
infect
neutropen
individu
viral
parasit
infect
rare
occur
isol
neutropenia
granulocyt
coloni
stimul
factor
gcsf
inject
help
rais
neutrophil
count
patient
complic
infect
sinc
stimul
releas
neutrophil
marrow
gcsf
use
bone
marrow
reserv
patient
congenit
immun
form
neutropenia
toler
persist
low
count
without
increas
incid
infect
monocytosi
occur
chronic
infect
inflammatori
condit
protozoan
infect
typhu
trypanosomiasi
kalaazar
may
associ
monocytosi
chronic
juvenil
myelomonocyt
leukaemia
malign
disord
monocytosi
may
sever
acut
monocyt
leukaemia
may
present
mild
moder
monocytosi
monocytosi
particularli
monocyt
lymphocyt
ratio
greater
may
indic
activ
progress
tuberculosi
unfavour
prognosi
normal
ratio
less
restor
heal
process
complet
decreas
absolut
monocyt
count
occur
bone
marrow
failur
state
aplast
anaemia
chemotherapi
low
monocyt
count
occur
overwhelm
sepsi
splenomegali
monocytopenia
characterist
featur
hairi
cell
leukaemia
consid
diagnost
hallmark
diseas
peripher
blood
contain
around
total
bodi
lymphocyt
popul
sinc
repres
cell
present
blood
transit
secondari
lymphoid
organ
wide
variat
exist
lymphocyt
count
individu
especi
childhood
lymphocyt
count
exhibit
diurnal
pattern
peak
night
nadir
morn
lymphocytosi
characterist
infecti
mononucleosi
mani
atyp
larg
lymphocyt
seen
peripher
blood
film
atyp
cell
also
occur
cytomegaloviru
infect
infecti
hepat
absolut
lymphocytosi
occur
chronic
infect
brucellosi
recoveri
stage
tuberculosi
lymphocytosi
unusu
bacteri
infect
except
case
pertussi
heavi
smoke
also
often
overlook
caus
lymphocytosi
probabl
one
commonest
reason
mild
moder
increas
lymphocyt
count
malign
bone
marrow
disord
predominantli
acut
lymphoblast
chronic
lymphocyt
leukaemia
nonhodgkin
lymphoma
caus
lymphocytosi
lymphocyt
may
characterist
morpholog
chang
identifi
blood
film
eg
smear
cell
chronic
lymphocyt
leukaemia
correct
diagnosi
confirm
immunophenotyp
specif
combin
cell
marker
lymphopenia
due
decreas
product
redistribut
increas
rate
death
lymphocyt
decreas
product
usual
result
cytotox
drug
radiotherapi
increas
lymphocyt
death
occur
infect
influenza
hiv
occasion
isol
low
lymphocyt
count
context
otherwis
normal
full
blood
count
clue
diagnosi
hiv
reflect
destruct
cell
viru
although
expans
cell
may
rais
total
lymphocyt
count
normal
level
redistribut
rather
deplet
total
bodi
lymphocyt
number
occur
steroid
treatment
endogen
secret
corticosteroid
acut
ill
due
retent
lymphocyt
secondari
lymphoid
organ
eosinophilia
eosinophil
involv
innat
immun
hypersensit
number
circul
rel
small
compar
leukocyt
predominantli
resid
tissu
gut
skin
lung
entri
point
allergen
infect
commonest
caus
eosinophilia
helminth
infect
atopi
allerg
diseas
advers
drug
reaction
less
common
caus
classifi
umbrella
term
hypereosinophil
syndrom
tabl
sinc
parasit
infect
like
commonest
caus
eosinophilia
tropic
return
travel
extens
search
infect
undertaken
patient
persist
eosinophilia
initi
investig
determin
patient
histori
geograph
exposur
figur
absolut
number
eosinophil
peripher
blood
may
correl
tissu
distribut
potenti
caus
tissu
damag
granul
releas
degre
eosinophilia
depend
extent
tissu
invas
therefor
modest
tapeworm
roundworm
resid
bowel
much
higher
invas
occur
exampl
toxocara
cani
filaria
schistosomiasi
almost
alway
caus
eosinophilia
strongyloid
stercorali
capac
remain
host
decad
initi
infect
caus
vari
degre
eosinophilia
without
symptom
steroid
treatment
may
necessari
case
eosinophil
tissu
damag
exacerb
clinic
problem
patient
strongyloid
infect
parasit
infest
exclud
start
steroid
hypereosinophilia
mild
moder
eosinophilia
common
asthma
although
high
count
prompt
search
churgstrauss
syndrom
allerg
bronchopulmonari
aspergillosi
drug
includ
penicillin
caus
eosinophilia
diagnosi
made
note
recoveri
drug
discontinu
eosinophilia
featur
hodgkin
lymphoma
signifi
favour
prognosi
may
preced
origin
diagnosi
lymphoma
relaps
immunocompromis
patient
hiv
infect
find
eosinophilia
may
crucial
sinc
success
antiretrovir
treatment
may
depend
concomit
erad
parasit
thrombocytopenia
often
discov
incident
patient
full
blood
count
estim
platelet
count
l
usual
associ
symptom
bleed
clinic
evid
haemorrhag
occur
count
level
condit
coagul
defect
vascular
problem
rare
platelet
dysfunct
suspect
although
prime
role
platelet
haemostasi
sever
import
role
recogn
recent
year
includ
wound
repair
tissu
heal
antimicrobicid
properti
lymphangiogenesi
tumour
metastas
mainten
blood
vessel
integr
congenit
platelet
disord
often
part
syndrom
patient
wiskottaldrich
syndrom
small
platelet
associ
eczema
recurr
infect
congenit
platelet
disord
disord
present
deaf
cataract
skelet
deform
oculocutan
albin
common
syndrom
present
blood
film
morpholog
provid
import
clue
caus
thrombocytopenia
figur
fragment
red
cell
schistocyt
increas
possibl
microangiopath
haemolyt
anaemia
alter
vessel
wall
fibrin
format
blood
vessel
shred
erythrocyt
consum
platelet
thrombot
thrombocytopenia
purpura
haemolyt
urem
syndrom
dissemin
intravascular
coagul
present
thrombocytopenia
dysplast
red
white
cell
rais
suspicion
myelodysplasia
confirm
bone
marrow
examin
cytogenet
analysi
import
exclud
vitro
platelet
agglutin
caus
appar
thrombocytopenia
anticoagul
edta
depend
phenomenon
repeat
sampl
examin
use
citrat
anticoagul
rare
platelet
satellit
platelet
clump
round
neutrophil
caus
artefactu
thrombocytopenia
anaemia
affect
nearli
two
billion
peopl
global
much
higher
preval
develop
countri
compar
wealthi
nation
vs
contin
africa
highest
preval
asia
greatest
absolut
burden
account
anaem
popul
anaemia
burden
highest
among
children
women
reproduct
age
anaemia
contribut
matern
death
perinat
death
global
per
year
defin
anaemia
accord
variou
haemoglobin
concentr
tabl
appropri
threshold
question
wide
variat
haemoglobin
concentr
among
peopl
differ
race
preval
anaemia
use
indic
public
health
statu
nation
preval
anaemia
object
quantifi
anaemia
major
complic
sever
infect
includ
malaria
hiv
tuberculosi
neglect
tropic
diseas
among
commonest
problem
tropic
countri
incid
anaemia
chang
predict
fashion
alter
diseas
burden
preval
anaemia
use
assess
whether
intervent
reach
poorest
commun
haemoglobin
concentr
gl
recommend
diseas
surveil
highpreval
countri
chang
haemoglobin
use
monitor
impact
intervent
anaemia
tropic
countri
box
often
due
infect
chronic
health
problem
diabet
chronic
respiratori
diseas
cancer
relat
complic
increas
caus
partli
due
lifestyl
chang
bodi
compens
drop
haemoglobin
content
reason
haemoglobin
level
drop
extrem
low
level
symptom
develop
anaemia
present
symptom
exert
breathless
palpit
case
syncop
attack
patient
chronic
anaemia
may
also
multitud
nonspecif
symptom
includ
poor
concentr
decreas
work
perform
easi
exhaust
tabl
thorough
histori
clinic
examin
may
provid
clue
caus
anaemia
investig
often
necessari
confirm
diagnosi
guid
treatment
howev
mani
resourcepoor
set
access
routin
biochem
haematolog
test
scarc
much
relianc
place
clinic
examin
intern
guidelin
integr
manag
childhood
ill
recommend
diagnosi
anaemia
sick
children
base
assess
palmar
pallor
pregnant
women
symptom
fatigu
dyspnoea
combin
sign
conjunctiv
palmar
pallor
increas
respiratori
rate
suggest
anaemia
howev
make
diagnosi
anaemia
base
clinic
assess
alon
unreli
unless
anaemia
sever
specif
anatom
site
particularli
accur
predict
anaemia
though
sensit
may
increas
use
multipl
site
central
laboratori
lowincom
countri
autom
haematolog
analys
sever
manual
method
exist
assess
haemoglobin
concentr
suitabl
rural
area
main
electr
eg
haemoglobin
colour
scale
hemocu
techniqu
haemoglobin
colour
scale
principl
colour
fingerprick
blood
sampl
soak
special
chromatographi
paper
compar
clinic
symptom
sign
anaemia
vari
depend
caus
speed
onset
rapid
drop
haemoglobin
much
like
caus
symptom
anaemia
chronic
anaemia
slowli
develop
anaemia
allow
time
mani
case
one
condit
coexist
individu
adequ
respons
treatment
anaemia
requir
manag
contributori
factor
intrauterin
growth
thu
low
birth
weight
prematur
associ
iron
deplet
postnat
period
sever
intervent
suggest
improv
infantil
iron
defici
includ
delay
cord
clamp
deliveri
short
delay
minut
allow
small
import
amount
blood
continu
flow
foetu
placenta
improv
infant
feed
practic
prevent
treatment
infecti
diseas
intervent
prevent
low
birth
weight
matern
nutrit
supplement
control
infect
chronic
health
problem
pregnanc
anaemia
young
children
due
increas
nutrit
requir
period
rapid
growth
requir
may
time
higher
per
kilogram
bodi
weight
adult
male
addit
infant
toddler
diet
often
lack
bioavail
iron
casecontrol
studi
preschool
children
malawi
sever
anaemia
haemoglobin
concentr
gl
identifi
bacteraemia
malaria
hookworm
hiv
infect
defici
vitamin
b
commonest
caus
anaemia
lack
folat
iron
uncommon
lowincom
countri
multipl
interdepend
caus
anaemia
often
oper
one
individu
rectifi
singl
factor
unlik
make
big
impact
resolv
anaemia
intervent
use
prevent
anaemia
younger
children
includ
micronutri
supplement
food
fortif
deworm
prevent
treatment
infecti
diseas
school
nutrit
programm
communitybas
nutrit
promot
defin
anaemia
pregnanc
haemoglobin
level
less
gl
haematocrit
less
time
pregnanc
onefifth
matern
mortal
attribut
anaemia
pregnanc
anaemia
affect
nearli
half
pregnant
women
worldwid
matern
anaemia
associ
mani
factor
might
also
causal
associ
mortal
includ
poverti
infect
inadequ
healthseek
behaviour
global
import
caus
anaemia
pregnanc
iron
defici
although
hookworm
malaria
hiv
infect
defici
folat
micronutri
may
contribut
pregnancyassoci
complic
includ
septicaemia
preeclampsia
obstetr
problem
precipit
anaemia
import
note
diagnosi
iron
defici
pregnanc
reli
ferritin
measur
may
mislead
highqual
digit
exampl
known
haemoglobin
concentr
colour
repres
gl
increment
gl
gl
method
inexpens
depend
skill
scientist
durabl
dusti
hot
dri
humid
condit
probabl
better
clinic
diagnosi
detect
mild
moder
degre
anaemia
disadvantag
requir
specif
chromatographi
paper
good
natur
light
detect
chang
haemoglobin
less
gl
small
batteryor
mainsoper
machin
use
drop
blood
plastic
cuvett
produc
direct
readout
haemoglobin
second
simpl
use
produc
accur
consist
result
one
decim
place
inbuilt
qualitycheck
mechan
hemocu
specif
design
tropic
condit
oper
temperatur
dusti
humid
condit
howev
recurr
cost
associ
dispos
plastic
cuvett
mean
littl
opportun
costsav
highvolum
workload
iron
statu
infant
directli
proport
bodi
mass
blood
volum
reflect
major
caus
anaemia
case
iron
defici
effect
describ
individu
iron
defici
without
obviou
featur
anaemia
three
intervent
strategi
recommend
prevent
anaemia
pregnanc
weekli
iron
folic
acid
supplement
women
reproduct
age
daili
iron
folic
acid
supplement
pregnanc
presumpt
treatment
hookworm
infect
pregnanc
area
hookworm
infect
known
endem
sever
factor
may
interfer
efficaci
intervent
underparticip
antenat
care
may
common
due
factor
geograph
distanc
low
motiv
poor
interperson
skill
health
staff
poor
qualiti
suppli
facil
insuffici
suppli
iron
folic
acid
pill
women
poor
understand
daili
use
supplement
especi
face
common
side
effect
subsaharan
africa
acut
shortag
high
turnov
health
worker
lack
time
also
shown
contribut
ineffect
antenat
measur
reduc
anaemia
interestingli
studi
bangladesh
show
first
pill
whether
taken
daili
basi
less
frequent
yield
benefit
rais
haemoglobin
level
suggest
current
recommend
dose
may
higher
necessari
achiev
optim
outcom
except
anaemia
sever
global
burden
iron
defici
estim
anaemia
preval
survey
includ
mani
differ
caus
anaemia
data
may
unreli
often
base
proven
case
iron
defici
estim
global
women
preschool
children
affect
irondefici
anaemia
make
number
select
risk
factor
prevent
death
disabl
worldwid
iron
defici
begin
childhood
worsen
adolesc
girl
aggrav
pregnanc
poor
iron
store
birth
low
iron
content
breast
milk
low
dietari
iron
intak
throughout
infanc
childhood
result
high
preval
anaemia
childhood
anaemia
exacerb
increas
requir
adolesc
iron
loss
menstruat
often
compound
lack
adequ
nutrit
situat
worsen
pregnanc
iron
requir
approxim
two
time
higher
nonpregn
state
iron
defici
consid
diagnosi
secondari
outcom
due
underli
medic
condit
although
may
physiolog
respons
rapid
growth
increas
requir
childhood
pregnanc
still
requir
treatment
due
potenti
deleteri
consequ
mani
chronic
effect
iron
defici
may
develop
clinic
laboratori
evid
anaemia
becom
appar
biochem
evid
iron
defici
occur
sever
step
initi
iron
store
bone
marrow
deplet
reflect
decreas
serum
ferritin
total
ironbind
capac
start
rise
serum
iron
satur
begin
fall
microcytosi
drop
haemoglobin
ensu
attempt
identifi
earli
iron
defici
anaemia
develop
order
improv
neurolog
psychomotor
function
children
work
perform
adult
widespread
iron
supplement
howev
concern
iron
excess
may
promot
infect
especi
malari
area
rang
laboratori
investig
usual
necessari
iron
defici
suspect
tabl
diagnosi
confirm
search
precis
caus
necessari
systemat
approach
investig
iron
defici
see
requir
base
understand
alter
iron
absorpt
transport
cycl
defici
intak
cow
milk
poor
iron
content
caus
gut
blood
loss
infant
rare
defect
haem
biosynthesi
iron
transport
irondefici
individu
may
symptom
excess
fatigu
nonspecif
sign
anaemia
becom
pronounc
anaemia
develop
consumpt
unusu
food
ice
paint
pica
occur
minor
individu
physic
examin
may
reveal
stomat
glossiti
koilonychia
spoonshap
nail
hair
loss
oesophag
web
describ
plummervinson
syndrom
rare
may
respond
iron
replac
sinc
iron
import
neuromuscular
develop
sever
featur
anaemia
describ
tabl
may
relat
iron
defici
treatment
iron
defici
dietari
modif
oral
parenter
iron
blood
transfus
reserv
sever
symptom
especi
anaemia
develop
rapidli
haemoglobin
level
alon
consid
criterion
transfus
sinc
low
level
eg
gl
may
appropri
treat
oral
iron
anaemia
develop
slowli
intraven
iron
consid
case
poor
respons
intoler
oral
iron
cereal
poultri
green
leafi
veget
contain
nonhaem
iron
often
poorli
absorb
dietari
histori
suggest
defici
diet
food
rich
haem
iron
red
meat
liver
recommend
social
religi
custom
financi
statu
allow
ideal
drink
contain
vitamin
c
facilit
iron
absorpt
absorpt
also
facilit
take
supplement
empti
stomach
although
side
effect
dyspepsia
may
alway
allow
strategi
heavi
tea
intak
interfer
iron
absorpt
avoid
multivitamin
dietari
supplement
contain
calcium
zinc
copper
also
interfer
iron
absorpt
absorpt
may
delay
tetracyclin
milk
soft
drink
sinc
acid
necessari
iron
absorpt
antacid
may
account
poor
respons
oral
iron
iron
usual
prescrib
daili
dose
mg
element
iron
commonli
ferrou
sulphat
tablet
three
time
daili
dose
children
mgkg
per
day
split
divid
dose
assum
good
complianc
absorpt
result
increas
haemoglobin
within
week
haemoglobin
normal
iron
continu
month
replenish
iron
store
major
problem
oral
iron
upper
gastrointestin
sideeffect
dosedepend
reduct
dose
chang
formul
glucon
fumar
even
liquid
form
may
success
liquid
iron
prepar
may
stain
teeth
therefor
taken
straw
oral
iron
also
caus
constip
diarrhoea
dosedepend
parenter
iron
best
given
intraven
intramuscular
iron
pain
associ
develop
soft
tissu
sarcoma
highmolecularweight
iron
dextran
carri
low
signific
risk
anaphylaxi
newer
formul
includ
lowmolecularweight
iron
dextran
iron
sucros
ferumoxytol
iron
glucon
minim
risk
vitamin
b
cobalamin
defici
wellrecogn
caus
macrocyt
anaemia
box
although
microorgan
synthes
cobalamin
human
need
obtain
essenti
vitamin
food
mainli
meat
poultri
dairi
product
vitamin
b
essenti
cofactor
dna
synthesi
serv
cofactor
two
key
biochem
process
involv
methylmalon
acid
homocystein
precursor
consequ
vitamin
b
defici
interfer
dna
synthesi
clinic
manifest
includ
haematolog
megaloblast
anaemia
pancytopenia
neuropsychiatr
disord
paraesthesia
peripher
neuropathi
psychosi
dementia
increas
risk
cardiovascular
diseas
hyperhomocystinaemia
systemat
approach
investig
vitamin
b
defici
requir
understand
absorpt
cycl
ingest
vitamin
b
broken
acid
environ
stomach
bind
rbinder
gastric
secret
saliva
stabil
vitamin
b
alkalin
environ
small
intestin
vitamin
b
releas
rbinder
bind
intrins
factor
synthes
gastric
pariet
cell
vitamin
b
intrins
factor
complex
absorb
termin
ileum
recent
altern
absorpt
system
independ
intrins
factor
termin
ileum
postul
provid
rational
mean
cell
volum
use
diagnost
clue
confirmatori
also
low
thalassaemia
sideroblast
anaemia
rare
lead
poison
fals
normal
presenc
iron
defici
older
peopl
coexist
megaloblast
anaemia
anaemia
chronic
diseas
occasion
caus
microcytosi
serum
ferritin
use
laboratori
measur
iron
statu
low
valu
diagnost
presenc
anaemia
high
valu
usual
exclud
iron
defici
acutephas
protein
increas
inflammatori
condit
certain
malign
make
unreli
also
increas
tissu
damag
especi
liver
level
fals
decreas
vitamin
c
defici
hypothyroid
erythrocyt
zinc
protoporphyrin
intermedi
haem
biosynthesi
elev
concentr
indic
interrupt
haem
synthesi
due
iron
defici
zinc
incorpor
place
iron
measur
drop
blood
portabl
haematofluoromet
small
sampl
size
make
use
screen
test
field
survey
particularli
children
pregnant
women
inflammatori
state
may
coexist
red
cell
wash
measur
serum
bilirubin
fluoresc
compound
like
drug
give
fals
high
valu
although
often
done
lead
poison
give
fals
high
valu
rare
acut
myeloid
leukaemia
sideroblast
anaemia
give
slightli
high
valu
use
increas
thalassaemia
recommend
normal
level
haem
iron
studi
serum
iron
concentr
repres
iron
enter
leav
circul
rang
vari
wide
age
circadian
rhythm
infect
iron
ingest
total
iron
bind
capac
measur
iron
bound
transferrin
rais
level
suggest
iron
defici
transferrin
satur
ratio
serum
iron
tibc
express
percentag
probabl
use
detect
iron
overload
rather
low
level
sensit
indic
fall
within
day
onset
irondefici
reduc
level
shown
predictor
iron
defici
especi
set
renal
insuffici
fals
normal
valu
occur
mcv
increas
thalassaemia
serum
transferrin
receptor
increas
inflammatori
condit
may
upregul
increas
erythropoiesi
haemolyt
diseas
give
fals
high
valu
serum
transferrin
receptor
ferritin
ratio
suggest
case
bone
marrow
examin
special
iron
stain
perl
absenc
stainabl
iron
sampl
contain
particl
establish
diagnosi
without
laboratori
test
simultan
control
specimen
contain
stainabl
iron
also
assess
use
differenti
anaemia
chronic
disord
milder
form
thalassaemia
help
identifi
sideroblast
anaemia
ring
sideroblast
perl
stain
form
congenit
dyserythropoiet
anaemia
also
caus
microcytosi
improv
haemoglobin
clinic
symptom
iron
replac
probabl
simplest
way
diagnos
iron
defici
peripher
smear
may
help
demonstr
pencil
cell
anisopoikilocytosi
high
platelet
number
case
blood
loss
treatment
vitamin
b
defici
oral
parenter
rout
increas
evid
suggest
oral
supplement
may
adequ
even
presenc
malabsorpt
pernici
anaemia
recommend
initi
oral
replac
dosag
mg
higher
dose
may
need
malabsorpt
pernici
anaemia
patient
sever
anaemia
andor
neurolog
diseas
daili
altern
day
intramuscular
inject
initi
first
week
revert
mainten
threemonthli
dose
reticulocytosi
earli
marker
respons
treatment
notic
within
week
folic
acid
defici
caus
similar
haematolog
manifest
vitamin
b
defici
though
neuropsychiatr
manifest
less
common
abil
nerv
tissu
concentr
folat
level
five
time
greater
plasma
suggest
reason
absenc
neuropathi
folat
defici
folic
acid
defici
associ
fetal
neural
tube
defect
possibl
increas
atherosclerosi
arterioven
thrombosi
dementia
colon
cancer
dietari
folic
acid
present
form
polyglutam
convert
folat
monoglutam
enzym
folat
conjugas
intestin
brush
border
prior
absorpt
monoglutam
function
carbon
transport
essenti
dna
biosynthesi
folat
found
green
veget
fruit
defici
result
decreas
intak
impair
absorpt
increas
util
although
commonest
caus
dietari
insuffici
wealthi
countri
cereal
fortifi
folic
acid
success
prevent
vitamin
defici
howev
folat
defici
continu
problem
less
wealthi
countri
particularli
among
children
pregnant
women
exclus
feed
goat
milk
infant
lead
folat
defici
caus
includ
alcohol
excess
cook
veget
malabsorpt
eg
abnorm
small
bowel
increas
demand
folic
acid
occur
pregnanc
grow
foetu
high
avid
folat
reason
folat
supplement
wide
recogn
essenti
part
routin
antenat
care
reduc
risk
neural
tube
defect
high
folat
util
also
occur
haemolyt
anaemia
sickl
cell
diseas
due
high
red
cell
turnov
exfoli
dermat
sever
drug
includ
sulfasalazin
trimethoprim
methotrex
pyrimethamin
phenytoin
also
interfer
folat
metabol
folatedefici
individu
develop
macrocyt
anaemia
peripher
blood
bone
marrow
find
similar
found
vitamin
b
defici
diagnosi
folat
defici
confirm
presenc
low
serum
folat
red
cell
folat
level
decreas
slowli
serum
level
turnov
red
cell
red
cell
folat
level
may
better
indic
tissu
folat
level
serum
folat
although
red
cell
folat
expens
fals
low
vitamin
b
defici
treatment
folat
defici
oral
folat
mg
daili
suffici
even
malabsorpt
state
crucial
coexist
vitamin
b
defici
rule
initi
folic
acid
therapi
otherwis
neurolog
manifest
b
defici
may
deterior
rapidli
also
import
increasingli
popular
oral
replac
therapi
absorb
vitamin
b
bind
transcobalamin
ii
transport
around
bodi
diagnosi
vitamin
b
defici
base
measur
serum
vitamin
level
patient
clinic
evid
defici
note
caution
folic
acid
defici
caus
fals
low
serum
vitamin
b
level
diagnost
clue
vitamin
b
defici
includ
mark
macrocytosi
often
fl
neutrophil
nuclear
hypersegment
oval
macrocyt
peripher
blood
film
blood
test
may
demonstr
increas
lactat
dehydrogenas
low
haptoglobin
level
due
haemolysi
within
bone
marrow
caus
macrocytosi
confirm
bone
marrow
examin
reveal
megaloblast
pictur
although
macrocyt
anaemia
typic
featur
vitamin
b
defici
absent
older
individu
may
neuropsychiatr
featur
measur
methylmalon
acid
homocystein
level
two
marker
sensit
detect
b
defici
shown
vitamin
b
defici
occur
normal
haemoglobin
level
without
macrocytosi
pernici
anaemia
probabl
commonest
caus
vitamin
b
defici
presenc
pariet
cell
intrins
factor
antibodi
support
diagnosi
pernici
anaemia
schill
test
rare
perform
unavail
radiolabel
vitamin
b
difficulti
interpret
result
presenc
renal
insuffici
pernici
anaemia
begin
increas
risk
gastric
carcinoma
carcinoid
tumour
rare
congenit
disord
eg
imerslundgrasbeck
syndrom
neglect
tropic
diseas
group
infect
endem
develop
countri
sever
neglect
tropic
diseas
caus
anaemia
mani
manag
use
inexpens
intervent
treat
underli
parasit
infect
mechan
anaemia
condit
predominantli
blood
loss
gastrointestin
genitourinari
tract
also
poor
nutrit
bone
marrow
suppress
inflamm
hypersplen
haemolysi
anaemia
common
consequ
infect
soiltransmit
helminth
schistosoma
strong
correl
haemoglobin
level
worm
load
faecal
egg
count
even
mild
infect
lead
anaemia
polyparasit
ie
infect
sever
parasit
simultan
respons
unrespons
anaemia
erad
one
organ
treatment
commun
high
risk
soiltransmit
helminth
improv
growth
iron
store
children
reduc
anaemia
pregnant
women
treatment
anaemia
due
neglect
tropic
diseas
depend
erad
parasit
drug
albendazol
praziquantel
though
anaemia
resolut
may
less
success
due
trichuriasi
addit
iron
anthelmint
treatment
met
variabl
success
rate
probabl
associ
anaemia
relat
inflamm
howev
still
gener
recommend
iron
supplement
includ
anthelmint
therapi
treatment
programm
neglect
tropic
diseas
introduct
haemoglobin
hb
preval
mani
part
africa
also
area
middl
east
figur
hb
tend
common
among
ethnic
group
tradit
high
exposur
plasmodium
falciparum
malaria
subsaharan
africa
approxim
infant
born
sickl
cell
diseas
year
mostli
hbss
sickl
cell
diseas
scd
autosom
recess
disord
character
product
abnorm
haemoglobin
sickl
haemoglobin
sickl
haemoglobin
hb
aris
mutat
codon
gene
result
replac
normal
glutam
acid
residu
valin
scd
commonli
caus
coinherit
two
sickl
cell
gene
homozyg
hb
ss
diseas
patient
heterozyg
hb
anoth
haemoglobin
mutat
hbc
haemoglobin
sc
diseas
also
present
featur
scd
ss
diseas
diseas
sever
sc
diseas
diseas
box
scd
affect
multipl
organ
clinic
cours
punctuat
episod
acut
ill
background
progress
organ
damag
especi
central
nervou
system
lung
first
descript
scd
anaem
grenadian
dental
student
next
year
underli
caus
folat
defici
identifi
treat
vitamin
import
erythropoiesi
iron
metabol
enhanc
iron
absorpt
releas
store
bone
marrow
decreas
risk
infect
vitamin
defici
major
public
health
problem
lowincom
countri
estim
million
preschool
children
affect
pregnant
women
women
childbear
age
also
constitut
highrisk
group
vitamin
defici
vitamin
given
thai
school
children
conjunctiv
xerosi
led
signific
increas
haemoglobin
level
anaem
school
children
tanzania
vitamin
supplement
produc
mark
increas
haemoglobin
enhanc
coadministr
iron
vitamin
also
improv
anaemia
pregnant
women
depend
local
preval
defici
though
respons
may
suboptim
pregnant
women
infect
hiv
copper
trace
element
necessari
normal
haematopoiesi
myelopoiesi
anaemia
copper
defici
due
decreas
activ
copperdepend
enzym
hephaestin
ceruloplasmin
cytochrom
c
oxidas
import
ferrousferr
iron
convers
decreas
lead
abnorm
iron
absorpt
incorpor
haemoglobin
molecul
acquir
copper
defici
occur
malnutrit
gastrointestin
malabsorpt
syndrom
coeliac
diseas
cystic
fibrosi
individu
gastrectomi
surgeri
result
short
bowel
also
risk
copper
defici
also
describ
person
ingest
excess
amount
zinccontain
supplement
swallow
zinccontain
coin
anaemia
relat
copper
defici
normocyt
macrocyt
associ
neutropenia
thrombocytopenia
rare
bone
marrow
find
characterist
cytoplasm
vacuol
erythroid
myeloid
precursor
cell
ring
sideroblast
unusu
find
iron
granul
plasma
cell
find
may
misdiagnos
myelodysplast
neoplasm
measur
serum
copper
level
help
confirm
diagnosi
although
test
fairli
insensit
sinc
almost
complet
haematolog
recoveri
occur
copper
replac
may
use
diagnost
test
oral
copper
supplement
start
mg
element
copper
day
slowli
decreas
next
week
mg
good
respons
note
although
low
zinc
level
caus
anaemia
link
growth
retard
heighten
suscept
infect
male
hypogonad
relat
sickl
cell
diseas
zinc
defici
describ
nearli
half
children
adult
sickl
cell
diseas
possibl
due
increas
loss
zinc
urin
high
cell
turnov
decreas
dietari
intak
contrast
zinc
excess
caus
anaemia
interfer
copper
absorpt
sequest
gut
lumen
reason
zinc
compound
use
treat
wilson
diseas
character
copper
excess
howev
repeat
sickl
unsickl
eventu
caus
irrevers
chang
earli
manag
avoid
repeat
crise
import
prevent
diseas
progress
polymer
therefor
clinic
featur
scd
influenc
three
main
factor
hypoxia
intracellular
hb
concentr
coexist
genet
haemoglobin
abnorm
eg
hereditari
persist
fetal
haemoglobinhaemoglobin
f
sickl
red
cell
lead
vasoocclus
haemolysi
due
entrap
sickl
erythrocyt
microvasculatur
upregul
adhes
receptor
white
blood
cell
contribut
process
provid
inflammatori
discov
hypoxia
led
red
cell
sickl
scd
aris
tendenc
hb
polymer
hypox
state
phenomenon
occur
deoxygen
due
bind
chain
two
haemoglobin
molecul
properti
uniqu
haemoglobin
variant
substitut
polymer
haemoglobin
fill
erythrocyt
deform
architectur
flexibl
form
sickl
shape
alter
structur
promot
cellular
dehydr
upon
reoxygen
polym
dissolv
thu
revers
sickl
process
exposur
cold
fever
menstruat
alcohol
intak
dehydr
precipit
pain
crise
unlik
acut
pain
crise
chronic
pain
scd
usual
identifi
basi
femor
head
necrosi
osteoarthr
chronic
skin
ulcer
sickl
erythrocyt
averag
life
span
day
anaemia
due
sever
caus
box
red
cell
haemolysi
caus
anaemia
gall
stone
caus
fatigu
proport
anaemia
suggest
patient
low
haemoglobin
concentr
high
haemolyt
rate
like
develop
vascular
problem
compar
higher
haemoglobin
concentr
splenic
sequestr
sudden
rapid
drop
haemoglobin
occur
yet
develop
autosplenectomi
occur
young
children
hbss
adult
hbsc
diseas
sickl
thalassaemia
treatment
may
requir
blood
transfus
rare
case
sequestr
fatal
splenectomi
may
need
recurr
sever
sequestr
parent
taught
feel
infant
abdomen
enlarg
spleen
report
hospit
sudden
increas
spleen
size
red
cell
aplasia
develop
due
secondari
parvoviru
infect
predilect
erythroid
progenitor
alloimmun
common
scd
patient
frequent
transfus
possibl
extend
red
cell
phenotyp
undertaken
hyperhaemolyt
crisi
suspect
sudden
exacerb
anaemia
increas
reticulocytosi
bilirubin
level
infecti
complic
scd
major
caus
morbid
mortal
even
adequ
vaccin
prophylact
antibiot
regimen
propens
infect
relat
impair
splenic
function
although
tissu
ischaemia
especi
lung
renal
system
contribut
hyposplen
demonstr
peripher
blood
film
presenc
howelljolli
bodi
children
scd
undergon
autosplenectomi
age
year
therefor
increas
risk
infect
encapsul
microorgan
typic
infecti
complic
includ
pneumococc
sepsi
neisseria
mening
osteomyel
caus
salmonella
speci
urinari
tract
infect
pyelonephr
due
escherichia
coli
anatom
abnorm
renal
papillari
necrosi
predispos
urinari
complic
may
requir
longterm
antibiot
acut
chest
syndrom
ac
defin
new
pulmonari
infiltr
chest
radiograph
combin
one
environ
activ
platelet
coagul
system
also
contribut
vasoocclus
scd
infant
scd
protect
first
month
life
high
level
haemoglobin
f
red
cell
anaemia
usual
develop
month
age
chronic
haemolysi
abnorm
red
cell
mean
scd
associ
steadi
state
haemoglobin
level
gl
although
organ
affect
scd
complic
occur
age
certain
featur
tend
predomin
differ
age
group
box
pain
hallmark
scd
four
differ
pattern
pain
describ
scd
differ
underli
mechan
vasoocclus
acut
intermitt
pain
bone
tissu
necrosi
chronic
neuroplast
chronic
neuropath
function
brain
chang
opioidinduc
hyperalgesia
acut
chronic
pain
crise
often
start
young
children
dactyl
handfoot
syndrom
pain
swell
hand
feet
result
inflamm
metacarp
metatars
periosteum
crise
result
vasoocclus
bone
marrow
caus
bone
infarct
releas
mediat
activ
pain
receptor
number
sever
frequenc
pain
episod
vari
wide
individu
half
may
never
episod
wherea
may
need
hospit
admiss
time
year
three
pain
episod
requir
hospit
per
year
associ
increas
mortal
among
patient
year
old
underresourc
set
hospit
visit
underestim
frequenc
pain
box
manifest
fever
cough
sputum
product
tachypnoea
dyspnoea
newonset
hypoxia
ac
common
caus
death
scd
patient
frequent
caus
hospit
second
pain
crisi
mortal
patient
ac
wealthi
countri
set
children
adult
peak
incid
ac
year
age
gradual
declin
per
patientyear
subject
older
year
fever
cough
common
children
ac
chest
pain
dyspnoea
common
adult
ac
often
preced
febril
pulmonari
infect
children
vasoocclus
pain
crisi
lung
infarct
adult
import
note
although
tachypnoea
wheez
featur
chest
infect
may
identifi
third
patient
may
normal
physic
examin
onethird
patient
ac
hypoxaem
oxygen
satur
chest
radiographi
essenti
although
infiltr
may
lag
behind
clinic
symptom
day
repeat
chest
xray
recommend
strong
clinic
suspicion
ac
bilater
infiltr
involv
multipl
lobe
may
predict
poorer
prognosi
risk
factor
ac
box
includ
fat
embolu
confirm
find
stainabl
fat
pulmonari
macrophag
chronic
complic
pulmonari
hypertens
occur
mani
patient
appear
associ
prior
episod
ac
high
serum
phospholipas
surrog
marker
creactiv
protein
note
patient
admit
vasoocclus
crisi
hour
develop
ac
stroke
neurolog
complic
occur
least
patient
scd
scd
one
common
caus
stroke
children
scd
risk
first
stroke
age
age
year
age
year
thrombot
haemorrhag
stroke
occur
although
former
common
children
year
age
wherea
latter
common
age
year
agespecif
pattern
may
relat
higher
cerebr
flow
rate
earli
childhood
although
preval
clinic
overt
stroke
order
clinic
silent
infarct
detect
magnet
reson
scan
affect
nearli
doubl
number
age
silent
infarct
associ
cognit
impair
major
children
requir
lifelong
specialist
care
cerebr
thrombosi
account
stroke
scd
result
largevessel
occlus
wherea
silent
infarct
result
microvascular
occlus
thrombosi
hypoxia
secondari
largevessel
diseas
third
scd
patient
majorvessel
stenosi
accompani
collater
vessel
appear
puff
smoke
moyamoya
angiographi
risk
factor
ischaem
stroke
scd
includ
increas
cerebr
blood
flow
veloc
previou
silent
infarct
nocturn
hypoxaemia
sever
anaemia
acut
chest
syndrom
elev
systol
blood
pressur
elev
leukocyt
count
risk
factor
haemorrhag
stroke
diagnosi
often
famili
histori
clinic
find
clearli
point
toward
diagnosi
scd
acut
crisi
abund
sickl
red
cell
seen
blood
film
white
cell
count
higher
normal
scd
diseas
particularli
patient
age
year
presenc
sickl
haemoglobin
differ
sickl
syndrom
eg
hba
hbss
hbsc
tabl
confirm
simpl
sickl
slide
solubl
test
haemoglobin
electrophoresi
distinguish
mani
variant
highperform
liquid
chromatographi
isoelectr
focus
prefer
definit
diagnosi
haemoglobin
mass
spectrometri
dna
analysi
increasingli
use
antenat
screen
avail
women
countri
help
identifi
coupl
risk
babi
scd
commun
accept
reproduct
genet
servic
howev
depend
effect
educ
counsel
use
prophylact
penicillin
provis
comprehens
medic
care
first
year
life
reduc
mortal
relat
scd
less
manag
box
individu
scd
best
manag
multidisciplinari
team
may
requir
varieti
specialist
input
includ
haematolog
ophthalmolog
nephrolog
obstetr
orthopaed
physiotherapi
cornerston
scd
therapi
diseas
modif
prompt
effect
manag
crise
sever
pain
crise
gener
requir
intraven
fluid
adequ
often
opiat
analgesia
box
diseas
modif
base
intervent
increas
hbf
level
steadi
state
usual
practic
give
sickl
cell
patient
folat
supplement
mgday
high
rate
haemopoiesi
put
risk
defici
scd
associ
function
asplenia
patient
also
receiv
prophylact
oral
penicillin
mg
twice
day
vaccin
encapsul
organ
hydroxycarbamid
main
agent
use
increas
hbf
box
associ
signific
reduct
acut
pain
crise
hospit
rate
time
first
second
pain
crise
episod
acut
chest
syndrom
need
transfus
number
unit
transfus
benefici
effect
hydroxycarbamid
independ
increas
hbf
includ
reduc
neutrophil
count
increas
cellular
water
content
decreas
hb
concentr
chang
express
adhes
molecul
nitric
oxid
gener
hydroxycarbamid
may
also
altern
frequent
blood
transfus
prevent
recurr
stroke
children
lower
transcrani
doppler
veloc
underus
cheap
effect
drug
relat
concern
leukaemogen
shown
problem
use
nonmalign
condit
like
scd
two
main
approach
transfus
scd
simpl
topup
transfus
exchang
transfus
target
haemoglobin
level
scd
therapi
gl
haematocrit
higher
target
level
associ
hyperviscos
box
manag
complic
sickl
cell
diseas
inabl
maxim
concentr
urin
hyposthenuria
respons
water
depriv
earli
find
renal
tubular
acidosi
increas
urinari
tract
infect
glomerular
hyperfiltr
increas
creatinin
secret
low
serum
creatinin
characterist
young
patient
sickl
cell
anaemia
renal
dysfunct
present
even
normal
serum
creatinin
valu
microalbuminuria
common
childhood
adult
develop
nephroticrang
protein
loss
gross
haematuria
develop
due
microthrombin
renal
vessel
renal
medullari
carcinoma
nocturn
enuresi
treatment
base
earli
use
hydroxycarbamid
angiotensinconvert
enzym
inhibitor
children
clinic
signific
albuminuria
note
scd
case
relationship
acut
chest
syndrom
differ
pathophysiolog
mortal
risk
even
mild
pulmonari
hypertens
high
regular
blood
transfus
longterm
anticoagul
tri
hydroxycarbamid
may
decreas
risk
prostacyclin
analogu
epoprostenol
iloprost
receptor
antagonist
bosentan
phosphodiesteras
inhibitor
includ
sildenafil
calcium
channel
blocker
evalu
brief
recurr
stutter
may
occasion
last
mani
hour
lead
impot
usual
ischaem
lowflow
priapism
patient
educ
seek
medic
attent
hour
durat
detumesc
within
hour
necessari
retain
potenc
intraven
hydrat
analgesia
initi
consider
agonist
etilefrin
phenylephrin
penil
aspir
irrig
salin
agent
shunt
may
requir
sever
case
combin
exchang
transfus
assess
pain
intens
choos
analges
dosag
rout
administr
paracetamol
hydrat
consid
patient
oral
sustainedreleas
morphin
good
intraven
morphin
infus
children
young
adult
manag
mild
pain
rest
hydrat
weak
opioid
codein
admit
patient
pain
subsid
promptli
requir
opioid
treatment
fever
pallor
sign
respiratori
compromis
low
likelihood
receiv
appropri
care
home
pain
manag
individu
dose
take
account
prior
pain
manag
use
opioid
pain
pathway
target
differ
point
differ
agent
avoid
toxic
one
class
alway
look
caus
eg
infect
dehydr
etc
educ
avoid
exposur
precipit
empathet
reassur
support
benzodiazepin
may
help
reduc
anxieti
reexamin
patient
often
ensur
adequ
pain
relief
assess
sedat
respiratori
rate
avoid
opioid
overdos
assess
patient
respons
convent
dose
analgesia
must
rememb
sickl
cell
diseas
metabol
narcot
rapidli
research
evid
complic
acut
chest
syndrom
anaemia
alway
look
caus
eg
infect
multiorgan
failur
simpl
transfus
exchang
transfus
use
neither
appear
superior
short
cours
steroid
may
attenu
ac
may
also
increas
risk
rehospit
bronchodil
may
help
patient
wheez
inhal
nitric
oxid
shown
clear
benefit
sinc
coagul
activ
import
pathophysiolog
acut
chest
syndrom
treatment
lowmolecularweight
heparin
may
reduc
clinic
complic
transcrani
doppler
measur
cerebr
blood
flow
major
step
forward
identifi
individu
increas
risk
ischaem
stroke
valu
cm
second
impart
risk
stroke
within
next
year
regular
blood
transfus
reduc
incid
stroke
children
due
high
recurr
stroke
stop
transfus
continu
transfus
guid
transcrani
doppler
measur
stroke
develop
best
therapeut
strategi
exchang
transfus
probabl
need
done
monthli
neurosurg
revascular
consid
moyamoyalik
syndrom
new
stroke
occur
despit
transfus
haemoglobin
sc
result
coinherit
hb
hbc
highest
preval
west
africa
clinic
featur
diseas
manag
similar
hbss
diseas
splenomegali
splenic
infarct
splenic
sequestr
may
occur
adulthood
prolif
retinopathi
necessit
regular
ophthalm
review
age
year
compar
hbss
anaemia
less
mark
hb
sc
gl
fewer
sickl
cell
target
cell
blood
film
diagnosi
confirm
haemoglobin
electrophoresi
hplc
isoelectr
focuss
worsen
complic
exchang
transfus
aim
achiev
hb
complic
transfus
scd
includ
alloimmun
delay
haemolyt
transfus
reaction
iron
overload
high
rate
red
cell
antibodi
format
note
wealthi
countri
due
minor
blood
group
incompat
recipi
blood
donor
often
differ
ethnic
leukocyt
reduct
transfus
blood
routin
abo
rh
kell
match
patient
extend
phenotyp
match
alloantibodi
may
use
reduc
transfus
reaction
treatment
ac
predominantli
support
includ
adequ
pain
relief
antibiot
eg
macrolid
cephalosporin
continu
puls
oximetri
deliveri
supplement
oxygen
patient
hypoxaemia
incent
spirometri
prevent
atelectasi
infiltr
blood
transfus
indic
patient
develop
respiratori
distress
clinic
signific
fall
haematocrit
sign
follow
predict
sever
clinic
cours
addit
reason
consid
offer
hydroxyurea
hb
gl
wbc
l
hbf
renal
insuffici
due
scd
start
mgkg
per
day
nearest
mgday
poor
respons
increas
dose
increment
mg
kg
per
day
everi
week
max
mgkg
per
day
good
respons
requir
gday
adult
monitor
fbc
hbf
reticulocyt
everi
week
initi
everi
week
stabl
dose
monitor
biochemistri
profil
hydroxyurea
renal
excret
hepat
toxic
less
pain
persist
increas
hbf
usual
measur
everi
week
mean
cell
volum
persist
increas
haematocrit
sever
anaem
decreas
ldh
accept
toxic
improv
symptom
blood
paramet
may
take
month
therapi
seen
approxim
week
reticulocyt
count
less
expect
degre
anaemia
erythropoietin
defici
consid
aim
case
reduc
hb
level
exchang
transfus
may
consid
case
stroke
acut
chest
syndrom
respond
topup
transfus
major
surgeri
target
haemoglobin
concentr
gl
may
consid
case
organ
failur
surgeri
individu
sickl
cell
trait
hb
protect
sever
malaria
compar
individu
normal
haemoglobin
hbaa
probabl
due
innat
immunemedi
mechan
individu
sickl
cell
trait
hba
gener
asymptomat
normal
haemoglobin
normal
life
expect
uncommonli
complic
poor
perfus
renal
papilla
increas
bacteruria
may
occur
blood
film
gener
normal
diagnosi
confirm
haemoglobin
electrophoresi
hplc
isoelectr
focus
origin
descript
thalassaemia
origin
area
round
mediterranean
term
deriv
greek
thalasso
sea
haima
blood
epidemiolog
thalassaemia
one
common
singl
gene
disord
approxim
global
popul
carrier
thalassaemia
occur
throughout
tropic
wherea
respons
haemoglobin
bart
hydrop
fetali
concentr
predominantli
southeast
asia
lesser
extent
around
mediterranean
common
mediterranean
countri
part
africa
throughout
middl
east
indian
subcontin
southeast
asia
haemoglobin
e
preval
highest
cambodia
lao
thailand
reach
lower
preval
rate
indonesia
malaysia
singapor
vietnam
inherit
quantit
defici
chain
requir
make
normal
adult
haemoglobin
mutat
associ
develop
complet
list
avail
globin
gene
server
websit
http
globincs
psuedu
affect
protein
synthesi
lead
reduc
design
absent
design
product
chain
clinic
sever
thalassaemia
lessen
coexist
haemoglobin
abnorm
coinherit
increas
product
haemoglobin
f
normal
synthesi
regul
duplic
gene
chromosom
genotyp
usual
repres
usual
result
delet
one
occasion
point
mutat
critic
region
may
caus
nondelet
mutat
complet
abolish
express
ie
thalassaemia
partial
downregul
express
thalassaemia
thalassaemia
occur
heterozyg
homozyg
state
compound
heterozygot
form
tabl
underproduct
chain
due
three
four
gene
delet
give
rise
excess
fetal
adult
globin
chain
form
tetram
call
hb
bart
fetal
hbh
adult
rare
form
occur
associ
condit
mental
retard
myelodysplast
leukaemia
syndrom
pathophysiolog
figur
thalassaemia
caus
imbal
chain
synthesi
homozyg
excess
precipit
red
cell
precursor
cell
destroy
bone
marrow
result
ineffect
erythropoiesi
shorten
red
cell
surviv
red
cell
releas
bone
marrow
contain
abnorm
inclus
promot
destruct
cell
spleen
lead
clinic
symptom
sign
haemolysi
heterozygot
excess
degre
inadequ
erythropoiesi
much
less
homozyg
hbf
product
normal
tail
within
month
birth
hbf
product
continu
adulthood
effect
increas
hbf
product
prevent
precipit
excess
globin
chain
consequ
ineffect
erythropoiesi
howev
hbf
high
oxygen
affin
lead
increas
erythropoietin
product
thu
increas
bone
marrow
expans
pathophysiolog
henc
clinic
manifest
quit
differ
excess
chain
form
solubl
tetram
rather
precipit
minim
ineffect
erythropoiesi
clinic
abnorm
hbh
may
splenomegali
secondari
increas
work
load
destruct
red
cell
contain
inclus
rare
anaemia
may
sever
enough
requir
blood
transfus
classif
divid
thalassaemia
major
transfusiondepend
thalassaemia
intermedia
abl
maintain
adequ
haemoglobin
without
transfus
requir
less
unitsyear
thalassaemia
minor
asymptomat
infant
protect
sever
anaemia
presenc
haemoglobin
f
usual
asymptomat
clinic
manifest
thalassaemia
major
depend
whether
adequ
blood
transfus
avail
stringenc
iron
chelat
undertaken
untreat
patient
thalassaemia
major
die
late
infanc
earli
childhood
effect
sever
anaemia
receiv
sporad
transfus
may
surviv
longer
suffer
secondari
effect
anaemia
boni
deform
growth
retard
clinic
featur
major
divid
result
anaemia
boni
chang
iron
overload
anaemia
defect
erythropoeisi
decreas
red
cell
surviv
increas
haemolysi
thalassaemia
major
lead
cardiac
decompens
failur
thrive
growth
retard
children
splenomegali
increas
work
load
cull
red
cell
inclus
bodi
caus
dilut
anaemia
drop
haemoglobin
compensatori
extramedullari
haematopoiesi
lead
hepatomegali
occasion
vertebr
compress
neurolog
defect
haemolysi
increas
red
cell
destruct
associ
gall
stone
individu
anoth
consequ
acceler
haemolysi
increas
incid
thromboembol
thalassaemia
major
intermedia
exposur
neg
charg
phospholipid
red
cell
membran
gener
red
cell
platelet
microparticl
splenectomi
postop
thrombocytosi
risk
factor
thrombosi
especi
combin
endotheli
oxid
stress
iron
overload
procoagul
comorbid
condit
diabet
mellitu
hormon
therapi
thrombophil
mutat
atrial
fibril
folat
defici
hyperuricaemia
occasion
gout
observ
thalassaemia
major
due
high
turnov
red
cell
enhanc
erythropoiet
drive
anaemia
thalassaemia
lead
increas
marrow
expans
homozyg
synthesi
markedli
reduc
absent
excess
form
tetram
form
precipit
red
cell
precursor
lead
intramedullari
destruct
cell
destruct
process
red
cell
membran
occur
format
hemichrom
shown
red
cell
inclus
degrad
product
excess
red
cell
may
releas
bone
marrow
destroy
spleen
lead
clinic
symptom
sign
haemolysi
sinc
affect
individu
synthesi
hbf
hba
continu
unab
haemoglobin
high
oxygen
affin
lead
increas
erythropoietin
product
thu
increas
bone
marrow
expans
splenomegali
may
massiv
growth
retard
children
boni
chang
unusu
complic
includ
infect
leg
ulcer
gall
stone
acut
haemolysi
respons
drug
infect
sever
clinic
featur
relat
molecular
basi
nondelet
type
hbh
diseas
sever
affect
haemoglobin
bart
occur
almost
exclus
asian
especi
chines
cambodian
thai
popul
infant
hb
bart
hydrop
fetali
syndrom
pallor
gross
oedema
sign
cardiac
failur
mark
hepatosplenomegali
skelet
cardiovascular
deform
often
gross
hypertrophi
placenta
mani
clinic
manifest
condit
explain
characterist
boss
skull
overgrowth
maxillari
region
radiolog
note
hair
end
sunray
appear
metatars
metacarp
bone
first
expand
measur
metacarp
bone
consid
good
indic
initi
transfus
therapi
skelet
deform
includ
shorten
long
bone
due
earli
epiphys
fusion
overgrowth
maxilla
caus
dental
malocclus
marrow
expans
also
lead
patholog
fractur
earli
bone
thin
osteoporosi
ineffect
drainag
sinus
middl
ear
skull
bone
overgrowth
caus
chronic
sinu
ear
infect
growth
retard
primarili
result
anaemia
contribut
iron
overload
hypersplen
defici
thyroid
growth
hormon
hypogonad
zinc
defici
chronic
liver
diseas
malnutrit
psychosoci
stress
patient
increas
iron
absorpt
mediat
reduc
hepcidin
receiv
regular
transfus
may
also
develop
transfus
siderosi
inadequ
chelat
iron
deposit
parenchym
tissu
varieti
clinic
consequ
box
process
may
modul
variant
haemochromatosi
hfe
gene
thalassaemia
intermedia
character
haemoglobin
concentr
gl
children
usual
present
around
year
age
symptom
anaemia
jaundic
hepatosplenomegali
may
also
skelet
chang
expans
facial
bone
obliter
maxillari
sinus
sever
molecular
factor
includ
coinherit
b
hereditari
persist
haemoglobin
f
c
specif
polymorph
contribut
convers
thalassaemia
major
intermedia
type
contrast
patient
thalassaemia
major
iron
load
thalassaemia
intermedia
occur
mainli
result
increas
intestin
iron
absorpt
rather
transfus
therapi
ineffect
erythropoiesi
result
chronic
anaemia
hypoxia
suppress
hepcidin
regul
iron
metabol
lead
increas
iron
absorpt
excess
iron
tend
accumul
liver
rather
heart
clinic
complic
thalassaemia
intermedia
includ
gallston
extramedullari
haemopoiesi
leg
ulcer
thromboembol
event
pulmonari
hypertens
major
caus
heart
failur
individu
although
individu
thalassaemia
intermedia
usual
need
regular
blood
transfus
evid
complic
particularli
later
life
may
less
common
regularli
transfus
patient
carrier
trait
loss
gene
usual
asymptomat
may
detect
routin
blood
count
show
mild
moder
microcyt
hypochrom
anaemia
antenat
counsel
may
indic
mother
possibl
fetu
may
risk
haemoglobin
bart
haemoglobin
h
diseas
occur
mainli
asian
occasion
mediterranean
popul
result
delet
three
gene
produc
anaemia
vari
gl
usual
associ
hypogonad
frequent
complic
patient
preval
male
femal
usual
hypogonadotroph
suggest
iron
damag
anterior
pituitari
hypothalamu
featur
rang
total
absenc
sexual
develop
delay
puberti
femal
normal
menstrual
function
fertil
normal
ovarian
function
preserv
although
secondari
amenorrhoea
develop
damag
ovari
rare
like
appear
older
women
around
high
vascular
activ
ovari
age
secondari
hypogonad
common
older
men
serum
ferritin
ngml
risk
factor
hypothyroid
second
common
endocrin
disord
although
mani
may
subclin
varieti
commonli
hypothyroid
primari
type
secondari
central
hypothyroid
increasingli
diagnos
recent
year
preval
diabet
mellitu
around
mean
age
diagnosi
year
impair
glucos
toler
occur
first
microvascular
damag
like
retin
chang
less
common
convent
form
erythroid
precursor
destruct
osmot
fragil
reduc
sometim
strikingli
sinc
case
red
blood
cell
haemolys
even
distil
water
reason
sophist
test
avail
osmot
fragil
use
screen
test
thalassaemia
trait
serum
zinc
level
may
low
may
relat
abnorm
growth
vitamin
c
level
may
also
low
due
increas
convers
oxal
acid
presenc
iron
overload
care
may
need
folic
acid
commenc
background
bone
marrow
failur
due
folat
defici
may
precipit
pain
erythropoiet
crise
manag
comprehens
manag
plan
patient
thalassaemia
may
involv
transfus
therapi
iron
chelat
splenectomi
prevent
earli
treatment
complic
stem
cell
transplant
mainstay
treatment
sever
form
thalassaemia
blood
transfus
aim
reduc
anaemia
erythropoiet
drive
howev
mani
lowincom
set
blood
suppli
inadequ
mani
thalassaem
patient
chronic
undertransfus
tabl
transfus
frequenc
guid
clinic
symptom
sign
poor
growth
facial
bone
abnorm
take
account
potenti
diseasemodifi
comorbid
although
decis
transfus
base
pure
haemoglobin
level
valu
gl
often
use
trigger
regular
transfus
prevent
alloimmun
extend
red
cell
antigen
type
c
e
kell
addit
abo
rh
type
carri
prior
first
transfus
transfus
full
crossmatch
screen
new
antibodi
undertaken
risk
alloimmun
appear
greater
patient
begin
transfus
therapi
first
year
life
develop
alloantibodi
autoantibodi
may
result
increas
transfus
requir
haemolysi
use
leukodeplet
techniqu
result
less
alloimmun
fewer
febril
transfus
reaction
sinc
storag
red
cell
anticoagul
solut
may
decreas
efficaci
use
blood
store
less
day
may
benefici
patient
requir
frequent
transfus
use
rel
blood
donor
discourag
especi
patient
candid
stem
cell
transplant
patient
thalassaemia
major
need
lifelong
regular
blood
transfus
mlkg
per
month
unit
blood
everi
week
maintain
pretransfus
haemoglobin
level
gl
clinic
benefit
regular
transfus
programm
includ
normal
growth
suppress
erythropoiesi
bone
marrow
expans
reduc
hepatosplenomegali
overal
sens
wellb
allow
normal
ageappropri
activ
higher
target
pretransfus
haemoglobin
level
gl
may
necessari
patient
heart
diseas
medic
condit
patient
achiev
adequ
suppress
bone
marrow
activ
lower
haemoglobin
level
shorter
interv
transfus
may
reduc
overal
blood
requir
need
balanc
patient
work
school
schedul
lifestyl
issu
iron
chelat
therapi
improv
surviv
rate
thalassaem
patient
prevent
hepat
fibrosi
ironinduc
cardiac
diseas
patient
compliant
chelat
therapi
normal
growth
sexual
develop
iron
chelat
box
usual
initi
children
year
receiv
unit
blood
andor
steadyst
serum
ferritin
level
ngml
least
two
occas
level
iron
overload
typic
occur
year
transfus
desferrioxamin
start
mgkg
per
day
children
initi
avoid
toxic
due
chelat
mark
splenomegali
often
treat
splenectomi
common
thalassaemia
patient
advent
regular
transfus
programm
sever
haemolysi
thalassaemia
relat
hyperact
spleen
aggrav
anaemia
increas
transfus
requir
although
earli
initi
regular
transfus
therapi
sever
thalassaemia
usual
occur
first
year
life
patient
thalassaemia
intermedia
need
sporad
transfus
first
two
decad
life
may
later
need
regular
transfus
fall
haemoglobin
level
develop
seriou
complic
haemoglobin
monitor
assess
rate
fall
haemoglobin
level
transfus
use
indic
frequenc
transfus
exchang
transfus
tri
way
reduc
iron
load
associ
reduct
blood
requir
onethird
tabl
sinc
unit
red
cell
contain
mg
iron
cumul
iron
burden
inevit
consequ
longterm
transfus
programm
addit
increas
iron
absorpt
gut
mgkg
per
day
respons
sever
anaemia
downregul
hepcidin
transfus
therapi
avert
splenomegali
hypersplen
still
develop
usual
children
year
age
individu
splenectomi
limit
complic
extramedullari
hematopoiesi
splenectomi
consid
annual
transfus
requir
reach
ml
red
blood
cellskg
per
year
usual
result
halv
transfus
requir
splenectomi
complic
includ
opportunist
infect
encapsul
organ
patient
therefor
receiv
appropri
vaccin
preoper
advis
seek
medic
advic
first
sign
infect
advis
delay
splenectomi
patient
least
year
old
increas
risk
overwhelm
sepsi
age
thalassaemia
patient
develop
thromboembol
complic
pulmonari
hypertens
splenectomi
partial
splenectomi
splenic
embol
attempt
minim
complic
studi
larg
trial
iron
overload
occur
organ
thalassaemia
patient
particularli
affect
heart
liver
endocrin
system
bone
occasion
pancrea
lung
iron
overload
need
detect
earli
treat
prevent
longterm
damag
annual
assess
iron
load
liver
heart
achiev
use
noninvas
method
magnet
reson
scan
detect
earli
chang
children
regular
growth
endocrin
assess
appropri
investig
carri
sign
development
delay
hormon
defici
osteoporosi
increasingli
recogn
prevent
ensur
adequ
dietari
calcium
intak
sun
exposur
vitamin
supplement
folic
acid
zinc
vitamin
e
vitamin
c
may
use
although
combin
vitamin
c
desferrioxamin
carri
risk
cardiac
toxic
allogen
stem
cell
transplant
current
mean
cure
thalassaemia
outcom
care
select
patient
measur
overal
eventfre
surviv
around
transplantrel
mortal
hepatomegali
liver
fibrosi
inadequ
iron
chelat
therapi
predict
poor
outcom
best
result
transplant
obtain
hlamatch
sibl
umbil
cord
blood
use
sourc
stem
cell
young
children
potenti
treatment
option
thalassaemia
outlin
box
prevent
sever
thalassaemia
birth
prenat
diagnosi
termin
pregnanc
success
countri
high
preval
thalassaemia
earli
identif
coupl
risk
cultur
sensit
genet
counsel
facilit
decisionmak
termin
continu
pregnanc
mean
corpuscular
haemoglobin
mch
use
screen
presenc
thalassaemia
use
cutoff
less
pg
rare
silent
mutat
may
present
mcv
pg
consid
posit
famili
histori
atrisk
coupl
refer
detail
counsel
option
prenat
diagnosi
includ
chorion
villou
sampl
amniocentesi
use
obtain
fetal
dna
sampl
genet
analysi
polymeras
chain
reaction
precis
hybrid
assay
detect
singl
point
mutat
use
small
dna
sampl
also
develop
less
invas
less
riski
option
isol
fetal
dna
circul
matern
blood
genet
analysi
preimplant
genet
diagnosi
newer
techniqu
dna
blastomer
use
genet
diagnosi
ultrasound
use
trimest
fetus
suspect
detect
sign
hydrop
fetali
enlarg
placenta
figur
hydroxyurea
help
patient
intermedia
effect
thalassaemia
major
histon
deacetylas
inhibitor
deriv
butyr
acid
intermitt
puls
hydroxycarbamid
tri
kit
ligand
decitabin
knockdown
regul
express
erythropoietin
vitamin
c
e
ferment
papaya
prepar
success
anim
model
use
retrovir
vector
transfer
human
gene
sequenc
promot
region
mice
stem
cell
gene
transfer
progenitor
hematopoiet
cell
human
also
studi
molecular
approach
tri
includ
use
differ
mutat
stop
codon
aberr
splice
partner
test
case
trait
protect
red
cell
red
cell
lack
sourc
nadph
sole
depend
pentos
phosphat
pathway
defici
leav
cell
defenc
oxid
damag
oxid
damag
result
denatur
haemoglobin
aggreg
form
heinz
bodi
denatur
haemoglobin
precipit
damag
cell
bind
membran
cytoskeleton
result
decreas
cellular
deform
also
destroy
spleen
result
haemolysi
level
enzym
activ
higher
young
erythrocyt
matur
cell
older
cell
suscept
haemolysi
global
distribut
defici
mirror
malaria
malaria
histor
preval
provid
degre
protect
malaria
class
iv
normal
enzym
activ
class
v
increas
activ
enzym
activ
enzym
variant
distinguish
electrophoret
mobil
b
wildtyp
enzym
common
variant
popul
african
descent
demonstr
normal
enzym
activ
associ
haemolysi
common
variant
associ
mild
moder
haemolysi
approxim
hb
e
caus
substitut
glutam
acid
lysin
codon
gene
caus
reduc
synthesi
chain
lead
thalassaemia
phenotyp
hb
e
affect
least
million
peopl
worldwid
import
health
problem
particularli
indian
subcontin
southeast
asia
area
replac
common
thalassaemia
disord
frequenc
hbe
reach
mani
region
thailand
lao
cambodia
estim
least
new
case
hbe
expect
next
decad
thailand
alon
natur
histori
hbe
thalassaemia
highli
variabl
patient
asymptomat
eg
heterozygot
hbe
homozygot
hbe
other
eg
hbe
may
transfusiondepend
pathophysiolog
dehydrogenas
defici
origin
recogn
associ
haemolysi
relat
eat
fava
bean
favism
primaquin
ingest
defici
common
enzym
defect
human
present
million
peopl
worldwid
figur
xlink
hereditari
defect
caus
mutat
gene
enzym
catalys
first
reaction
pentos
phosphat
pathway
produc
nadph
import
antioxid
use
preserv
reduc
form
glutathion
reduc
glutathion
act
scaveng
oxid
metabolit
therebi
african
carri
variant
mediterranean
present
countri
surround
mediterranean
sea
middl
east
india
indonesia
electrophoret
mobil
b
enzym
synthesi
catalyt
activ
reduc
sever
popul
mediterranean
coexist
clinic
manifest
defici
classifi
asymptomat
ii
acut
haemolyt
anaemia
iii
favism
iv
neonat
jaundic
v
chronic
nonspherocyt
haemolyt
anaemia
acut
haemolyt
anaemia
defici
secondari
infect
eg
pneumonia
hepat
b
typhoid
fever
oxid
drug
may
precipit
diabet
ketoacidosi
myocardi
infarct
strenuou
physic
exercis
list
drug
may
caus
haemolysi
individu
tabl
obtain
http
drug
deem
safe
individu
may
caus
haemolysi
other
due
heterogen
underli
genet
variant
haemolysi
typic
occur
within
day
commenc
drug
produc
intens
haemoglobinuria
fortun
disord
selflimit
patient
develop
renal
impair
anaemia
requir
transfus
spontan
recoveri
reflect
replac
older
enzymedefici
red
cell
younger
reticulocyt
withstand
oxid
injuri
precipit
caus
remov
haemoglobin
begin
recov
day
acut
renal
failur
due
acut
tubular
necrosi
tubular
obstruct
haemoglobin
cast
develop
complic
haemolysi
defici
occur
often
adult
children
may
requir
haemodialysi
occur
predominantli
boy
age
year
mediterranean
countri
also
observ
middl
east
asia
north
africa
intravascular
extravascular
haemolysi
occasion
sever
enough
caus
renal
impair
occur
eat
fresh
cook
fava
bean
favism
report
breastf
babi
mother
eaten
fava
bean
divicin
isouramil
implic
toxic
compon
fava
bean
neonat
jaundic
occur
onethird
male
babi
area
defici
common
like
due
defici
present
day
birth
lead
kernicteru
matern
exposur
oxid
drug
even
naphthalenecamphor
mothbal
precipit
haemolysi
affect
babi
breastfeed
mother
therefor
warn
avoid
offend
drug
umbil
potion
contain
fava
tripl
dye
menthol
appli
henna
skin
use
cloth
store
naphthalen
prematur
infant
babi
coinherit
mutat
gilbert
syndrom
particular
risk
phototherapi
exchang
transfus
therapi
may
requir
reduc
level
unconjug
bilirubin
diagnosi
may
easili
miss
assess
statu
undertaken
jaundic
infant
whose
famili
histori
ethnic
geograph
origin
suggest
likelihood
defici
infant
respond
poorli
phototherapi
unusu
manifest
defici
usual
present
childhood
may
histori
sever
neonat
jaundic
episod
worsen
anaemia
requir
blood
transfus
complic
gallston
although
individu
usual
wellcompens
anaemia
requir
transfus
exacerb
rare
may
becom
transfusiondepend
antioxid
vitamin
e
selenium
may
benefit
case
haemolysi
resolv
follow
splenectomi
folic
acid
supplement
necessari
support
increas
compensatori
erythropoiesi
diagnosi
defici
usual
suspect
neonat
jaundic
occur
area
defici
drug
may
caus
haemolysi
individu
common
episod
nonimmun
haemolyt
anaemia
occur
associ
infect
drug
appear
red
cell
blood
film
characterist
denatur
haemoglobin
concentr
one
area
within
cell
creat
helmet
bite
cell
denatur
haemoglobin
precipit
peripher
red
blood
cell
heinz
bodi
detect
stain
methyl
violet
definit
diagnosi
defici
quantit
spectrophotometr
analysi
rate
nadph
product
point
care
test
defici
develop
yet
valid
routin
use
measur
enzym
activ
episod
acut
haemolysi
help
sinc
reticulocytosi
featur
acut
haemolysi
produc
falseneg
result
high
enzym
level
younger
erythrocyt
manag
effect
manag
strategi
defici
prevent
haemolysi
avoid
trigger
agent
like
infect
drug
fava
bean
milder
variant
eg
class
iii
iv
drug
known
trigger
haemolysi
may
given
individu
defici
benefit
outweigh
risk
blood
count
close
monitor
eg
use
lowdos
primaquin
individu
avari
screen
programm
establish
mediterranean
popul
defici
preval
haematolog
complic
malaria
see
chapter
pathophysiolog
anaemia
malaria
multifactori
influenc
age
individu
antimalari
immun
statu
anaemia
mechan
malaria
involv
haemolysi
increas
red
cell
destruct
infect
bystand
erythrocyt
dyserythropoiesi
hypersplen
haemolysi
coexist
condit
caus
anaemia
haemolysi
common
nonimmun
individu
acut
malaria
wherea
dyserythropoiesi
predomin
mechan
anaemia
recurr
falciparum
malaria
haemolysi
result
red
cell
phagocytosi
reticuloendotheli
system
trigger
damag
red
cell
membran
exposur
abnorm
surfac
antigen
surfac
ten
uninfect
red
cell
remov
circul
infect
red
cell
destroy
possibl
relat
loss
red
cell
complement
regulatori
protein
increas
level
circul
immun
complex
may
partli
explain
persist
worsen
anaemia
follow
parasit
clearanc
poor
correl
parasitaemia
sever
anaemia
note
studi
increas
incid
anaemia
note
malaria
vaccin
trial
possibl
due
enhanc
clearanc
uninfect
red
blood
cell
decreas
erythropoeisi
abnorm
red
cell
precursor
reticulocytopenia
found
consist
examin
bone
marrow
malariainfect
patient
decreas
erythropoiesi
due
mani
factor
includ
low
level
high
level
abnorm
erythropoietin
decreas
burst
coloni
form
unit
cytokineinduc
suppress
red
cell
product
inhibitori
effect
malari
pigment
haemozoin
epidemiolog
malariarel
anaemia
commonli
seen
children
pregnant
women
preval
malari
anaemia
subsaharan
africa
children
pregnant
women
highest
preval
infant
children
less
year
age
infant
may
acquir
malaria
placenta
individu
live
malari
area
may
multipl
reason
anaemia
bacteraemia
hookworm
infect
vitamin
defici
make
difficult
assign
anaemia
sole
malaria
howev
anim
studi
fact
anaemia
improv
antimalari
treatment
suggest
direct
relationship
malaria
infect
anaemia
exampl
tanzanian
children
anaem
episod
thought
caus
malaria
defin
sever
anaemia
attribut
malaria
haemoglobin
concentr
gl
haematocrit
ii
parasitaemia
blood
iii
normocyt
blood
film
exclud
common
caus
anaemia
howev
aspect
definit
critic
blood
film
examin
routin
parasit
densiti
vari
endem
age
although
tradit
p
falciparum
associ
sever
malariarel
anaemia
p
vivax
also
major
risk
factor
sever
anaemia
especi
young
children
chronic
recurr
infect
p
vivax
anaemia
associ
recurr
bout
haemolysi
predominantli
uninfect
erythrocyt
increas
fragil
symptom
malari
anaemia
vari
neglig
profound
depend
degre
anaemia
rapid
onset
splenomegali
common
featur
malari
anaemia
role
spleen
remov
infect
uninfect
red
cell
blackwat
fever
character
intens
intravascular
haemolysi
haemoglobinuria
occasion
renal
failur
patient
malaria
may
relat
underli
defici
factor
poor
nutrit
defici
vitamin
micronutri
bacteraemia
hookworm
hiv
infect
may
coexist
malaria
contribut
anaemia
nonmalari
caus
anaemia
consid
patient
whose
anaemia
respond
malaria
treatment
manag
sever
malari
anaemia
involv
support
care
treatment
malaria
underli
condit
recoveri
malariaassoci
anaemia
slow
take
week
even
longer
episod
reinfect
children
blood
transfus
usual
reserv
haemoglobin
level
less
gl
gl
complic
respiratori
distress
parasit
red
cell
releas
von
willebrand
factor
multim
caus
widespread
platelet
aggreg
lead
thrombocytopenia
platelet
synthesi
bone
marrow
rel
well
maintain
infect
antiplatelet
antibodi
immun
complex
splenomegali
contribut
thrombocytopenia
thrombocytopenia
occur
individu
infect
malaria
irrespect
speci
plasmodium
thrombocytopenia
febril
patient
endem
area
increas
probabl
malaria
factor
individu
return
tropic
countri
fever
thrombocytopenia
highli
specif
malaria
infect
profound
thrombocytopenia
unusu
malariaassoci
thrombocytopenia
rare
associ
haemorrhag
manifest
clinic
consequ
platelet
aggreg
endotheli
bind
primarili
microvascular
ischaemia
may
manifest
renal
impair
cerebr
ischaemia
occlus
retin
vasculatur
even
case
skin
necrosi
bleed
unlik
although
sever
thrombocytopenia
petechia
purpura
may
develop
denot
extravas
red
cell
subcutan
tissu
continu
platelet
activ
consumpt
exacerb
bleed
decreas
circul
platelet
associ
increas
vascular
leakag
develop
oedema
platelet
transfus
rare
requir
platelet
count
gener
rise
rapidli
treat
underli
malaria
coagulopathi
disturb
whole
coagul
system
involv
coagul
factor
platelet
anticoagul
factor
fibrinolyt
system
case
malaria
parasit
red
cell
vascular
endothelium
parasit
red
cell
induc
express
tissu
factor
endotheli
cell
monocyt
releas
microparticl
cytokin
releas
platelet
clump
initi
blood
coagul
tilt
balanc
toward
procoagul
state
figur
anticoagul
factor
sever
deplet
malaria
protein
c
antithrombin
level
invers
correl
sever
falciparum
malaria
return
normal
treatment
malaria
concern
possibl
increas
risk
infect
associ
iron
supplement
children
malari
area
current
recommend
advoc
iron
defici
malaria
common
iron
supplement
withheld
appropri
antimalari
treatment
prevent
also
offer
best
way
prevent
malari
anaemia
prevent
malaria
infect
avoid
mosquito
bite
eg
use
bed
net
chemoprophylaxi
malaria
chemoprophylaxi
infanc
reduc
malaria
anaemia
children
hospit
sever
malari
anaemia
may
benefit
intermitt
prevent
malari
therapi
discharg
prevent
recurr
anaemia
daili
cotrimoxazol
prophylaxi
use
hivinfect
individu
shown
reduc
malaria
parasitaemia
anaemia
normal
platelet
life
span
day
reduc
less
day
malaria
infect
sever
factor
respons
thrombocytopenia
malaria
infect
common
increas
platelet
activ
aggreg
figur
platelet
activ
parasit
red
cell
express
surfac
tissu
factor
initi
coagul
platelet
aggreg
result
activ
endothelium
bind
platelet
sequest
vascular
bed
includ
cerebr
vasculatur
platelet
facilit
adhes
year
although
transfus
may
requir
sever
lifethreaten
case
anaemia
aggress
transfus
therapi
associ
fatal
pulmonari
emboli
due
acceler
haemolysi
dissemin
intravascular
coagul
respond
art
erythropoietin
may
consid
sinc
reduc
respons
hormon
antierythropoietin
antibodi
note
hiv
patient
erythropoietin
particularli
use
individu
whose
erythropoietin
level
less
iul
addit
increas
haemoglobin
also
improv
qualiti
life
erythropoietin
may
take
sever
week
achiev
full
effect
patient
replet
haematin
erythropoietin
rare
associ
thrombosi
pure
red
cell
aplasia
thrombocytopenia
common
find
hivinfect
patient
may
initi
manifest
hiv
infect
mani
patient
data
wealthi
countri
demonstr
platelet
count
less
l
patient
less
l
overal
coagulopathi
malaria
infect
unusu
occur
less
case
appear
common
adult
cerebr
malaria
may
present
gastrointestin
bleed
microvascular
ischaemia
brain
kidney
retina
occasion
dermal
vasculatur
prolong
prothrombin
time
activ
partial
thromboplastin
time
occur
patient
p
falciparum
infect
coagulopathi
appear
featur
p
vivax
infect
sinc
coagul
factor
need
deplet
less
normal
prolong
clot
time
test
normal
despit
activ
coagulopathi
manag
coagulopathi
aim
restor
balanc
proand
anticoagul
process
complex
requir
input
coagul
specialist
ideal
access
plasma
heparin
factor
concentr
wellequip
coagul
laboratori
anaemia
anaemia
common
hivinfect
individu
occur
initi
present
stage
diseas
thirtyseven
percent
patient
clinic
aid
incid
anaemia
haemoglobin
gl
high
rate
anaemia
persist
despit
combin
anti
retrovir
treatment
art
anaemia
directli
relat
mortal
hiv
infect
independ
risk
factor
includ
count
multipl
reason
anaemia
hivinfect
patient
box
often
coexist
individu
patient
bone
marrow
infect
mycobacteria
speci
histoplasma
cryptococcu
penicillium
marneffei
decreas
red
cell
product
detect
bone
marrow
examin
cultur
parvoviru
predilect
erythroid
progenitor
cell
caus
sever
anaemia
hivinfect
patient
serolog
test
parvoviru
unhelp
hivinfect
patient
viral
polymeras
chain
reaction
need
confirm
diagnosi
likelihood
parvovirusinduc
anaemia
increas
sever
anaemia
found
individu
hiv
haemoglobin
less
gl
haemophagocytosi
occur
hiv
infect
may
secondari
coinfect
mycobacteria
cytomegaloviru
epsteinbarr
herpesvirus
poor
nutrit
due
socioeconom
reason
hivrel
anorexia
malabsorpt
condit
affect
gastrointestin
tract
achlorhydria
may
contribut
anaemia
haemolyt
anaemia
occur
secondari
drug
concomit
phosphat
dehydrogenas
defici
reticulocytopenia
common
hiv
infect
reticulocyt
count
use
exclud
haemolysi
although
direct
coomb
test
may
posit
patient
hiv
infect
autoimmun
haemolysi
common
caus
anaemia
reduct
red
cell
precursor
also
note
children
africa
sever
anaemia
treatment
hivrel
anaemia
focu
start
art
elimin
factor
infect
vitamin
defici
may
contribut
anaemia
wealthi
countri
art
shown
reduc
anaemia
preval
within
month
start
treatment
nonhodgkin
lymphoma
nhl
note
associ
hiv
infect
earli
epidem
aidsdefin
ill
incid
nhl
time
greater
hivinfect
adult
infect
respons
nearli
onesixth
death
attribut
aid
sinc
introduct
haart
incid
type
nhl
decreas
approxim
outcom
hivinfect
patient
lymphoma
improv
set
clinic
trial
surviv
rate
compar
without
hiv
infect
incid
hodgkin
lymphoma
increas
posthaart
era
possibl
due
immun
reconstitut
increas
cell
evid
epsteinbarr
viru
ebv
infect
found
virtual
case
hodgkin
diseas
hivrel
lymphoma
box
see
also
lymphoma
broadli
divid
system
lymphoma
primari
central
nervou
system
lymphoma
incid
highli
aggress
lymphoma
either
burkitt
lymphoma
approx
diffus
larg
bcell
lymphoma
approx
much
higher
hivinfect
patient
without
infect
although
tcell
lymphoma
uncommon
hiv
diseas
increas
recent
year
incid
primari
central
nervou
system
lymphoma
hivaffect
individu
time
common
gener
popul
pathogenesi
nhl
hiv
infect
relat
inadequ
host
immun
respons
virus
oncogen
potenti
predominantli
ebv
human
herpesviru
kaposi
sarcomaassoci
herpesviru
allow
unregul
lymphoid
growth
accumul
genet
abnorm
b
cell
marker
bcell
activ
serum
immunoglobulin
free
light
chain
cell
count
suggest
predict
marker
develop
nhl
hiv
infect
extranod
leptomening
involv
bsymptom
occur
major
hivinfect
patient
nhl
bone
marrow
commonli
involv
common
extranod
site
involv
incid
moder
thrombocytopenia
l
though
higher
clinic
aid
thrombocytopenia
common
abus
drug
opportunist
infect
malign
disord
bone
marrow
eg
lymphoma
may
also
sideeffect
therapeut
drug
common
caus
thrombocytopenia
hiv
infect
immun
thrombocytopenia
may
associ
hepat
c
coinfect
produc
decreas
platelet
surviv
particularli
count
antiplatelet
antibodi
immun
complex
crossreact
antibodi
hiv
envelop
protein
platelet
occur
hivassoci
thrombocytopenia
may
also
contribut
gener
reactiv
oxygen
speci
platelet
product
also
affect
hiv
infect
may
explain
high
level
thrombopoietin
document
hivrel
thrombocytopenia
case
hivrel
thrombocytopenia
may
undergo
spontan
remiss
treatment
thrombocytopenia
usual
initi
associ
bleed
unusu
first
line
treatment
involv
antiretrovir
therapi
aim
achiev
undetect
plasma
hiv
viraemia
drug
may
associ
caus
thrombocytopenia
withdrawn
opportunist
infect
secondari
malign
treat
treatment
immun
thrombocytopenia
nonhiv
case
option
includ
short
cours
steroid
intraven
immunoglobulin
shortliv
respons
antid
splenectomi
although
multipl
caus
thrombocytopenia
hivposit
individu
one
devast
thrombot
microangiopathi
thrombot
thrombocytopen
purpura
ttp
combin
haemolyt
anaemia
microthrombi
poor
prognosi
symptom
nonspecif
may
includ
fever
headach
bleed
chang
conscious
ttp
suspect
urgent
blood
film
request
combin
thrombocytopenia
red
cell
fragment
highli
suggest
ttp
ttp
associ
hiv
infect
frequent
introduct
art
common
adher
treatment
poor
resist
therapi
develop
ttp
thought
due
endotheli
damag
unlik
situat
nonhivinfect
individu
low
level
use
predictor
outcom
treatment
ttp
involv
plasma
exchang
although
refractori
may
occur
correct
art
case
art
administ
case
import
maintain
adher
throughout
period
plasma
exchang
apheresi
facil
limit
plasma
infus
alon
ml
kg
per
day
may
also
produc
respons
art
also
administ
immedi
plasma
exchang
minim
drug
remov
patient
viral
load
less
copiesml
gener
requir
fewer
plasma
exchang
remiss
higher
load
surviv
patient
hivassoci
ttp
preart
era
rare
longer
year
even
plasma
exchang
steroid
treatment
patient
compliant
art
mortal
around
immedi
limit
amount
blood
loss
exposur
subendotheli
space
releas
factor
von
willebrand
factor
multim
bind
platelet
initi
platelet
adhes
endothelium
adher
platelet
releas
granul
attract
platelet
combin
fibrinogen
form
aggreg
activ
platelet
also
attract
coagul
factor
therebi
promot
clot
process
critic
part
clot
format
convers
prothrombin
thrombin
thrombinfacilit
convers
fibrinogen
fibrin
figur
haemostat
control
mechan
oper
throughout
clot
process
prevent
excess
clot
format
involv
protein
c
antithrombin
antifibrinolyt
system
alter
regulatori
pathway
lead
either
bleed
thrombot
complic
bleed
result
inadequ
vasoconstrict
due
vascular
problem
acquir
eg
viral
haemorrhag
fever
immun
vascul
congenit
eg
collagen
vascular
disord
qualit
quantit
abnorm
von
willebrand
factor
caus
von
willebrand
diseas
decreas
number
function
platelet
either
acquir
eg
aspirin
nsaid
congenit
eg
platelet
function
defect
qualit
eg
caus
inhibitor
coagul
factor
commonli
factor
viii
quantit
eg
haemophilia
abnorm
coagul
factor
increas
fibrinolysi
eg
viral
haemorrhag
fever
snake
bite
acquir
bleed
disord
commonli
caus
vitamin
k
defici
dissemin
intravascular
coagul
dic
platelet
disord
box
may
sometim
due
acquir
inhibitor
coagul
factor
initi
laboratori
test
patient
excess
bleed
therefor
includ
platelet
count
clot
screen
prothrombin
time
pt
activ
partial
thromboplastin
time
aptt
gastrointestin
tract
often
stomach
perian
region
hepat
involv
seen
quarter
case
associ
particularli
poor
prognosi
cn
diseas
may
asymptomat
diagnost
lumbar
punctur
may
requir
hivrel
lymphoma
frequent
present
poor
prognost
featur
elev
serum
lactat
dehydrogenas
level
older
age
lowest
nadir
cell
count
prior
nhl
diagnosi
develop
nhl
art
cumul
hiv
viraemia
also
poor
prognost
featur
formal
prognost
score
system
develop
take
account
count
type
hivrel
lymphoma
associ
characterist
clinic
laboratori
featur
primari
effus
lymphoma
aggress
lymphoma
character
effus
seros
caviti
absenc
tumour
mass
strongli
associ
infect
viru
identifi
nuclei
malign
cell
plasmablast
lymphoma
mainli
affect
oral
caviti
mucosa
jaw
typic
associ
epsteinbarr
viru
histolog
examin
biopsi
tissu
necessari
confirm
diagnosi
type
lymphoma
diagnost
difficulti
may
aris
hivrel
hyperplasia
lymph
node
biopsi
may
confus
lymphoma
histolog
appear
hivrel
lymphoma
may
differ
noninfect
individu
mani
opportunist
pathogen
may
mimic
appear
nhl
coexist
need
identifi
exclud
make
diagnosi
lymphoma
prior
widespread
use
art
convent
lymphoma
chemotherapi
result
consider
toxic
increas
opportunist
infect
high
mortal
art
facilit
use
convent
dose
chemotherapi
conjunct
haematopoiet
growth
factor
support
markedli
improv
outcom
patient
hivrel
lymphoma
overal
respons
rate
concomit
use
art
chemotherapi
therefor
recommend
especi
count
less
antibodi
includ
treatment
regimen
nhl
studi
includ
patient
hivrel
lymphoma
report
favour
outcom
antiretrovir
agent
zidovudin
best
avoid
combin
chemotherapi
add
myelosuppress
chemotherapi
didanosin
may
worsen
peripher
neuropathi
caus
taxan
vinca
alkaloid
hivinfect
patient
undergo
chemotherapi
receiv
adequ
antiinfect
prophylaxi
due
high
risk
opportunist
infect
pneumocysti
herp
simplex
zoster
candida
consolid
chemotherapi
stem
cell
transplant
use
success
relaps
hivrel
lymphoma
haemostasi
maintain
interact
vessel
wall
platelet
balanc
proand
anticoagul
factor
although
process
haemostasi
usual
consid
occur
stepwis
fashion
vivo
step
happen
virtual
simultan
activ
line
endothelium
trauma
cancer
cell
cytokin
trigger
vasoconstrict
test
pathway
given
arrow
correspond
box
complic
malign
infect
seriou
condit
high
mortal
patient
present
spontan
bruis
excess
bleed
minor
wound
venepunctur
site
may
also
sign
complic
renal
failur
acut
respiratori
distress
syndrom
microangiopath
haemolyt
anaemia
dic
associ
combin
deplet
clot
factor
ie
prolong
pt
aptt
fall
platelet
count
red
cell
fragment
blood
film
rais
ddimer
fibrin
degrad
product
reduc
fibrinogen
level
manag
dissemin
intravascular
coagul
includ
treat
remov
underli
caus
correct
haemostat
abnorm
combin
platelet
cryoprecipit
fresh
frozen
plasma
although
bleed
due
thrombocytopenia
unusu
unless
platelet
count
fall
l
bleed
may
occur
normal
platelet
count
normal
clot
screen
test
ie
pt
aptt
platelet
function
impair
eg
myelodysplast
syndrom
platelet
transfus
gener
requir
unless
activ
bleed
prior
surgeri
idiopath
thrombocytopen
purpura
idiopath
thrombocytopen
purpura
due
immun
destruct
platelet
usual
primari
associ
condit
lymphoma
infect
includ
hiv
may
present
incident
petechia
bruis
bleed
nose
gum
especi
platelet
count
less
fibrinogen
level
may
help
case
excess
fibrinolysi
tabl
difficult
venepunctur
caus
vitro
activ
clot
system
result
shorten
pt
aptt
similar
find
may
occur
chronic
dic
due
vivo
activ
pt
aptt
necessarili
good
predictor
bleed
risk
clot
disord
associ
thrombosi
eg
antiphospholipid
antibodi
prolong
aptt
shorten
aptt
associ
mark
elev
factor
viii
level
eg
pregnanc
may
predictor
deep
vein
thrombosi
prolong
thrombin
time
caus
quantit
qualit
fibrinogen
defici
heparin
fibrin
degrad
product
reptilas
time
help
distinguish
fibrinogen
abnorm
prolong
reptilas
time
heparin
therapi
normal
reptilas
time
defici
vitamin
k
due
poor
diet
small
bowel
diseas
bile
flow
obstruct
clot
factor
ii
vii
ix
x
depend
vitamin
k
fatsolubl
vitamin
vitamin
k
defici
therefor
caus
prolong
pt
aptt
newborn
infant
vitaminkdepend
clot
factor
drop
precipit
within
coupl
day
birth
caus
haemorrhag
diseas
newborn
particularli
affect
infant
prematur
exclus
breast
fed
expos
drug
tuberculosi
convuls
anticoagul
utero
babi
develop
bleed
skin
gut
bleed
umbil
stump
circumcis
vitamin
k
defici
respond
intraven
vitamin
k
mgday
day
oral
intraven
inject
sever
bleed
clot
abnorm
treat
fresh
frozen
plasma
haemorrhag
diseas
newborn
prevent
mg
intramuscular
vitamin
k
given
deliveri
dissemin
intravascular
coagul
dic
character
activ
haemostasi
widespread
fibrin
format
activ
fibrinolysi
consumpt
platelet
clot
factor
may
precipit
tissu
injuri
obstetr
desmopressin
ddavp
rel
inexpens
drug
increas
fviii
level
vwf
activ
within
minut
administr
use
mild
haemophilia
mild
von
willebrand
diseas
major
side
effect
headach
hyponatraemia
fluid
intak
restrict
l
day
tranexam
acid
mouthwash
may
help
oral
mucos
bleed
danazol
increas
factor
viii
ix
level
within
day
therefor
recommend
patient
recurr
haemarthrosi
central
nervou
system
bleed
carri
high
risk
recurr
thromboembol
episod
singl
event
may
associ
precipit
event
underli
risk
factor
thrombophilia
clinic
state
hypercoagul
suspect
patient
strong
famili
histori
thrombosi
recurr
unusu
thrombos
increas
affluenc
consequ
lifestyl
chang
mean
preval
thromboembol
rise
lowand
middleincom
countri
risk
factor
sedentari
work
obes
excess
alcohol
intak
smoke
addit
cardiovascular
risk
factor
compound
l
spontan
recoveri
occur
less
commonli
adult
children
import
exclud
caus
thrombocytopenia
drug
dic
sepsi
diagnosi
suspect
bone
marrow
examin
show
increas
number
platelet
precursor
treatment
prednisolon
mgkg
usual
necessari
bleed
excess
bruis
dose
reduc
slowli
platelet
count
improv
secondlin
treatment
includ
immunosuppress
agent
danazol
splenectomi
may
also
benefici
carri
increas
risk
infect
platelet
transfus
intraven
gammaglobulin
temporarili
increas
platelet
count
emerg
prior
surgic
procedur
inherit
bleed
disord
classifi
broadli
coagul
factor
defici
eg
factor
viii
factor
ix
defici
von
willebrand
diseas
platelet
disord
frequenc
gene
inherit
bleed
disord
throughout
world
haemophilia
preval
von
willebrand
diseas
haemophilia
b
condit
occur
frequent
among
popul
consanguin
marriag
common
prenat
diagnost
facil
unavail
gener
individu
inherit
coagul
factor
defici
present
soft
tissu
bleed
haemarthros
intramuscular
bleed
platelet
disord
von
willebrand
diseas
tend
present
mucos
bleed
howev
sever
type
iii
von
willebrand
diseas
present
sever
soft
tissu
bleed
mani
condit
diagnos
follow
excess
uncontrol
bleed
trauma
surgic
procedur
menorrhagia
delay
sever
postpartum
haemorrhag
may
present
featur
bleed
disord
particularli
von
willebrand
diseas
hypothyroid
caus
decreas
synthesi
von
willebrand
factor
inherit
platelet
function
disord
associ
characterist
syndrom
eg
oculocutan
albin
skelet
defect
may
provid
clue
diagnosi
earli
recognit
symptom
clinician
teacher
public
import
earli
treatment
establish
patient
inherit
bleed
disord
usual
manag
blood
product
box
chemotherapi
design
reduc
bleed
associ
complic
clot
factor
concentr
may
import
produc
local
fraction
plasma
includ
list
essenti
medicin
one
intern
unit
iu
fviii
clot
factor
concentr
per
capita
recommend
minimum
requir
countri
wish
achiev
optim
surviv
haemophilia
popul
estim
peopl
world
haemophilia
receiv
adequ
treatment
manag
patient
bleed
disord
reli
wellequip
qualiti
assess
laboratori
accur
diagnosi
monitor
treatment
access
plasma
compon
replac
therapi
appropri
support
servic
physiotherapi
orthopaed
counsel
also
avail
mani
countri
inherit
bleed
disord
associ
stigma
particularli
direct
mother
affect
children
acut
chronic
leukaemia
usual
associ
high
white
cell
count
acut
leukaemia
present
normal
even
subnorm
white
cell
count
morpholog
peripher
blood
bone
marrow
specimen
crucial
confirm
diagnosi
particularli
import
case
acut
leukaemia
children
may
mistaken
acut
viral
infect
stain
method
includ
sudan
black
b
myeloperoxidas
nonspecif
esteras
import
distinguish
differ
subtyp
acut
myeloid
lymphoid
leukaemia
therefor
guid
treatment
acut
myeloid
leukaemia
aml
preval
increas
age
success
rate
chemotherapi
protocol
high
even
sophist
centr
neutropenia
myelosuppress
requir
intens
blood
compon
support
occur
chemotherapi
bone
marrow
transplant
offer
best
option
cure
patient
relaps
manag
aml
therefor
complex
expens
hydroxycarbamid
subcutan
cytarabin
may
use
palli
treatment
acut
promyelocyt
leukaemia
aml
subtyp
must
distinguish
type
acut
myeloid
leukaemia
high
cure
rate
earli
treatment
predominantli
affect
young
adult
high
incid
certain
ethnic
group
especi
latin
american
descent
treatment
protocol
includ
alltransretino
acid
combin
chemotherapi
develop
feasibl
lowincom
countri
anoth
regimen
base
intraven
arsen
trioxid
develop
india
respons
rate
good
diseasefre
overal
surviv
condit
associ
thrombosi
hiv
infect
chronic
infect
includ
tuberculosi
helminthinduc
eosinophil
myocard
african
american
like
diagnos
pulmonari
embol
rather
deepvein
thrombosi
compar
racial
group
african
patient
thrombosi
tend
younger
report
literatur
higher
mortal
rate
around
possibl
due
late
present
poor
access
health
facil
asian
popul
seem
lower
preval
symptomat
venou
thrombosi
compar
african
american
littl
known
preval
prothrombot
factor
mutat
prothrombin
gene
defici
antithrombin
protein
c
protein
tropic
countri
although
high
rate
factor
v
leiden
risk
factor
venou
thrombosi
describ
tunisia
lupu
anticoagul
antiphospholipid
syndrom
associ
increas
thrombosi
risk
increas
afrocaribbean
popul
especi
presenc
hiv
also
describ
nigerian
women
preeclampsia
manag
venou
thrombosi
initi
heparin
warfarin
month
complianc
may
difficult
lowresourc
set
requir
regular
monitor
warfarin
therefor
import
tri
prevent
thrombos
remov
underli
risk
factor
treat
individu
risk
thrombosi
short
cours
prophylact
heparin
cover
procedur
known
associ
thrombosi
risk
present
venou
arteri
thromboembol
may
inherit
eg
defici
thrombin
protein
protein
c
acquir
eg
antiphospholipid
patient
person
famili
histori
result
clinic
imag
examin
confirm
thrombosi
may
suggest
diagnosi
laboratori
test
need
determin
caus
classifi
type
thrombophilia
interpret
complex
patient
recurr
unusu
thrombos
refer
specialist
centr
haematolog
malign
predominantli
leukaemia
lymphoma
myeloma
gener
approach
manag
condit
lowincom
countri
outlin
box
definit
treatment
undertaken
specialist
haematolog
unit
leukaemia
broadli
classifi
acut
chronic
lymphoid
myeloid
present
symptom
sign
relat
disturb
blood
cell
product
bone
marrow
due
effect
malign
cell
clone
box
acut
leukaemia
character
rapid
progress
poor
prognosi
left
untreat
wherea
chronic
leukaemia
gener
follow
much
slower
cours
mobil
commun
especi
parent
famili
rais
awar
among
local
council
govern
bodi
treatabl
cancer
benefit
cure
find
extern
partner
unit
local
nation
intern
alreadi
wellestablish
will
help
dictat
term
improv
support
care
facil
especi
protect
infecti
diseas
develop
safe
reliabl
blood
transfus
servic
provis
subsid
travel
satellit
clinic
lessen
burden
develop
appropri
protocol
diseas
entiti
local
practic
minimum
cost
maximum
efficaci
develop
medic
nurs
paramed
expertis
diseas
treat
initi
offer
visit
fellowship
long
term
train
individu
arrang
region
local
teach
programm
format
cooper
group
bring
togeth
profession
involv
special
within
countri
region
share
expertis
develop
train
programm
acut
lymphoblast
leukaemia
common
type
leukaemia
children
good
prognosi
treat
modern
chemotherapi
protocol
cure
rate
best
centr
exceed
lowincom
countri
cure
rate
much
lower
around
primarili
failur
complet
therapi
death
caus
treatment
consider
improv
outcom
achiev
twin
institut
develop
countri
specialist
centr
elsewher
countri
intern
measur
may
improv
outcom
focu
prevent
abandon
therapi
eg
provid
fund
transport
satellit
clinic
support
group
prompt
treatment
infect
treatment
dedic
paediatr
oncolog
unit
use
comprehens
multidisciplinari
team
approach
protocolbas
therapi
also
associ
improv
outcom
resourcepoor
set
chronic
myeloid
leukaemia
cml
manag
revolution
tyrosin
kinas
inhibitor
eg
imatinib
produc
complet
remiss
case
diagnosi
cml
establish
hydroxycarbamid
use
reduc
white
cell
count
follow
treatment
tyrosin
kinas
inhibitor
manufactur
provid
drug
free
charg
patient
lowincom
countri
confirm
cml
gener
form
tyrosin
kinas
inhibitor
becom
avail
chronic
lymphocyt
leukaemia
cll
occur
predominantli
older
peopl
usual
present
lymphadenopathi
recurr
infect
treatment
chlorambucil
prednisolon
although
aggress
form
requir
combin
therapi
rituximab
fludarabin
cyclophosphamid
treatment
gener
cur
diseas
may
indol
drug
may
requir
patient
symptom
risk
hyperviscos
high
lymphocyt
count
approxim
case
nonhodgkin
lymphoma
nhl
occur
equatori
belt
africa
year
tabl
mark
geograph
variat
preval
thought
relat
hiv
infect
burkitt
lymphoma
bcell
nhl
origin
describ
children
africa
estim
incid
per
million
lymphoma
broadli
classifi
hodgkin
lymphoma
nhl
nhl
divid
bcell
tcell
nkcell
immunodeficiencyassoci
type
clinic
present
lymphoma
character
enlarg
lymphoid
organ
subsequ
compress
adjac
structur
infiltr
organ
malign
lymphoid
cell
dysfunct
immunolog
system
manifest
immunosuppress
excess
dysregul
immun
activ
associ
exampl
autoimmun
condit
diagnosi
manag
variou
type
lymphoma
complic
undertaken
specialist
box
clinic
featur
leukaemia
fatigu
cardiac
symptom
anaemia
bleed
thrombocytopenia
increas
risk
infect
despit
higher
number
dysfunct
white
cell
lymphadenopathi
hepatosplenomegali
occur
although
lymphadenopathi
may
observ
monocyt
varieti
aml
blind
due
hyperviscos
hyperleukocytosi
tumour
lysi
syndrom
due
spontan
cell
lysi
present
renal
failur
pustul
pyogen
infect
skin
minor
wound
bleed
gum
characterist
featur
acut
monocyt
leukaemia
dissemin
intravascular
coagul
occur
acut
promyelocyt
leukaemia
gout
aris
breakdown
excess
white
cell
releas
uric
acid
oral
aphthou
ulcer
seen
sever
neutropenia
aml
granulocyt
sarcoma
chloroma
repres
extramedullari
deposit
leukaem
cell
organ
mainli
skin
may
occur
absenc
peripher
blood
involv
common
chromosom
transloc
aml
central
nervou
system
manifest
due
sludg
cerebr
circul
malign
cell
increas
intracrani
pressur
due
ventricular
blockad
occur
monocyt
myeloid
leukaemia
also
involv
mening
intracrani
haemorrhag
occur
high
white
cell
count
l
bone
pain
arthralgia
present
featur
children
quarter
children
may
present
limp
unwilling
walk
due
marrow
infiltr
leukaem
cell
rare
may
normal
blood
count
delay
diagnosi
anterior
mediastin
mass
thymu
enlarg
also
occur
children
young
adult
may
present
superior
venocav
obstruct
painless
enlarg
scrotum
sign
testicular
leukaemia
hydrocel
lymphat
obstruct
priapism
result
hyperleukocytosi
rare
often
asymptomat
usual
suspect
blood
count
chronic
cml
cll
tend
caus
gradualonset
symptom
sinc
patient
get
adjust
slowli
develop
anaemia
abdomin
discomfort
earli
satieti
featur
cml
due
excess
splenomegali
compress
stomach
reduc
lumin
volum
sternal
tender
may
note
cml
hyperleukocytosi
cml
occur
often
aml
due
gradual
increas
white
cell
caus
symptom
like
hyperuricaemia
gout
tinnitu
priapism
central
nervou
system
disturb
left
shoulder
tip
pain
aris
splenic
infarct
massiv
splenomegali
cml
cml
rare
present
featur
thyrotoxicosi
heat
intoler
weight
loss
excess
sweat
due
hypermetabol
cll
often
associ
lymphadenopathi
rare
mild
moder
splenomegali
acut
lymphoid
leukaemia
aml
acut
myeloid
leukaemia
cll
chronic
lymphocyt
leukaemia
cml
chronic
myeloid
leukaemia
centr
diagnosi
depend
clinic
histori
examin
radiolog
investig
document
extent
diseas
morpholog
immunohistochemistri
molecular
studi
tissu
sampl
confirm
lymphoma
subtyp
guidanc
diagnosi
treatment
lymphoma
set
resourc
limit
includ
recommend
panel
immunostain
chemotherapi
regimen
minim
need
support
care
telepatholog
involv
transmit
histolog
imag
via
internet
expert
oversea
may
help
certain
circumst
though
depend
qualiti
histolog
prepar
imag
appropri
diagnost
region
sampl
treatment
regimen
lymphoma
differ
accord
subtyp
may
involv
chemotherapi
radiotherapi
high
remiss
rate
achiev
burkitt
lymphoma
combin
cyclophosphamid
vincristin
methotrex
progress
diseas
manag
ifosfamid
mesna
cytosin
arabinosid
adult
tcell
leukaemialymphoma
atll
adult
tcell
leukaemialymphoma
atll
uncommon
lymphoid
malign
occur
patient
infect
human
tlymphotrop
viru
type
htlvi
endem
caribbean
western
africa
peru
southern
japan
less
infect
htlvi
develop
atll
year
elaps
primari
infect
develop
atll
suggest
addit
factor
need
malign
transform
atll
present
acut
approxim
case
although
chronic
form
also
describ
clinic
present
gener
lymphadenopathi
case
hepatosplenomegali
half
atll
associ
high
risk
hypercalcaemia
occur
twothird
patient
cours
diseas
may
associ
central
nervou
system
disturb
renal
impair
lytic
bone
lesion
occur
paraneoplast
type
lymphoma
identifi
select
countri
subsaharan
africa
phenomenon
due
product
parathormonelik
peptid
tcell
disord
atll
involv
skin
produc
eg
erythroderm
plaqu
diagnosi
atll
suspect
high
peripher
blood
white
blood
cell
count
combin
hypercalcaemia
characterist
lymphocyt
convolut
hyperlobul
nuclei
diagnosi
confirm
histolog
examin
tissu
lymph
node
bone
marrow
immunophenotyp
specif
cell
marker
proof
htlv
infect
usual
serolog
method
manag
atll
primarili
combin
chemotherapi
intrathec
prophylaxi
combin
zidovudin
interferon
agent
htlv
also
tri
success
hypercalcaemia
opportunist
infect
sought
treat
earli
patient
high
white
cell
count
associ
signific
risk
tumour
lysi
syndrom
prevent
adequ
hydrat
judici
use
allopurinol
uratereduc
agent
myeloma
monoclon
prolifer
plasma
cell
particularli
affect
older
peopl
myeloma
appear
less
common
asian
countri
elsewher
although
last
year
almost
fourfold
increas
incid
myeloma
occur
taiwan
unit
state
incid
multipl
myeloma
black
popul
twice
white
popul
abund
plasma
cell
infiltr
bone
marrow
interfer
normal
haematopoiesi
lead
anaemia
present
featur
individu
boni
infiltr
malign
plasma
cell
produc
osteoporosi
lytic
lesion
patholog
fractur
patient
myeloma
involv
bone
lead
hypercalcaemia
may
present
featur
vertebr
fractur
lead
spinal
cord
compress
malign
plasma
cell
produc
paraprotein
caus
renal
impair
hyperviscos
may
ensu
patient
paraprotein
product
control
patient
myeloma
may
need
varieti
support
intervent
includ
manag
anaemia
renal
failur
hypercalcaemia
hyperviscos
infect
bone
pain
specif
antimyeloma
treatment
manag
within
specialist
unit
undergon
radic
chang
last
decad
use
thalidomid
newer
formul
expens
proteasom
inhibitor
eg
bortzomib
thalidomid
rel
safe
effect
although
somnol
constip
sometim
troublesom
risk
thrombosi
thalidomid
especi
initi
therapi
prophylaxi
heparin
warfarin
antiplatelet
agent
depend
assess
risk
may
warrant
melphalan
may
also
use
particularli
resourc
limit
specialist
centr
howev
myelosuppress
regular
monitor
blood
count
essenti
maintain
adequ
blood
suppli
major
challeng
lowincom
countri
global
blood
suppli
donat
poorest
countri
world
popul
live
blood
transfus
vital
compon
everi
countri
health
servic
lifesav
intervent
ill
sever
acut
anaemia
mistak
transfus
process
lifethreaten
either
immedi
year
later
transmiss
infecti
agent
clinician
need
understand
blood
acquir
risk
benefit
use
appropri
govern
transfus
servic
need
put
measur
place
ensur
blood
safe
transfus
reach
need
time
manner
member
state
meet
world
health
organ
recommend
nation
qualiti
blood
transfus
system
nation
level
transfus
servic
director
advisori
committe
clear
transfus
polici
strategi
tabl
recommend
standard
blood
collect
test
distribut
although
central
servic
may
offer
best
guarante
qualiti
often
practic
countri
poorli
develop
commun
transport
infrastructur
two
system
central
hospitalbas
exist
lowincom
countri
manag
blood
suppli
central
system
voluntari
blood
donor
recruit
screen
bled
region
centr
blood
collect
distribut
peripher
hospit
hospitalbas
system
predomin
sourc
blood
across
subsaharan
africa
hospitalbas
system
obtain
blood
predominantli
rel
patient
blood
screen
use
within
local
vicin
blood
central
system
cost
least
three
time
much
per
unit
hospitalbas
system
although
central
system
save
cost
batch
bulk
purchas
qualiti
assur
process
donor
recruit
compon
expens
difficult
maintain
without
depend
extern
fund
hospitalbas
transfus
servic
test
qualiti
variabl
famili
patient
bear
cost
find
blood
donor
vast
major
blood
lowincom
countri
transfus
whole
blood
highincom
countri
standard
practic
optim
use
donat
blood
separ
individu
compon
whether
approach
costeffect
lowincom
countri
indic
transfus
differ
known
compon
may
includ
plasma
platelet
cryoprecipit
prepar
centrifug
use
close
steril
system
compon
differ
storag
requir
plasma
cryoprecipit
kept
frozen
red
cell
store
platelet
constant
agit
recent
evid
suggest
warm
fresh
whole
blood
may
better
compon
therapi
resuscit
acidot
hypotherm
coagulopath
trauma
patient
patient
need
massiv
transfus
mani
infect
transmit
blood
transfus
transfus
infect
blood
caus
morbid
mortal
recipi
econom
emot
impact
famili
commun
becom
infect
blood
transfus
infecti
other
contribut
spread
diseas
therebi
increas
burden
health
servic
reduc
product
labour
strategi
recruit
blood
donor
provid
blood
need
time
manner
ensur
blood
safe
possibl
safest
type
blood
donor
one
donat
regularli
ie
repeat
donor
state
safest
sourc
blood
altruist
voluntari
unpaid
donor
member
state
report
least
blood
suppli
voluntari
donor
lowincom
countri
abl
increas
recruit
voluntari
donor
sever
year
recent
evid
subsaharan
africa
indic
focu
voluntari
donor
may
misplac
sinc
firsttim
voluntari
donor
similar
preval
transfusiontransmit
infect
famili
replac
donor
order
limit
blood
shortag
maintain
constant
blood
suppli
poorer
countri
voluntari
replac
donor
accept
encourag
donat
regularli
mechan
convert
famili
replac
donor
repeat
voluntari
donor
potenti
significantli
increas
blood
donat
africa
polit
openminded
way
improv
suppli
safeti
blood
essenti
promot
evidencebas
approach
blood
transfus
practic
poorer
countri
support
strategi
wealthi
countri
major
transfus
carri
elect
contrast
poorer
countri
particularli
malaria
transmiss
rate
high
transfus
given
lifethreaten
emerg
lowincom
countri
transfus
administ
children
predominantli
malariarel
anaemia
pregnant
women
transfus
significantli
reduc
mortal
children
sever
anaemia
within
first
day
hospit
admiss
success
malaria
control
reduc
paediatr
transfus
requir
subsaharan
africa
inhospit
matern
death
sever
bleed
due
lack
blood
transfus
special
signific
user
blood
surgeri
trauma
emerg
medicin
gener
medicin
lowincom
countri
effect
way
avoid
transfus
reduc
preval
anaemia
studi
efficaci
cost
combin
intervent
includ
insecticidetr
bed
net
nutrit
supplement
anthelmint
drug
prevent
anaemia
need
resourc
limit
govern
may
need
make
difficult
decis
order
achiev
equit
balanc
invest
transfus
servic
public
health
measur
reduc
anaemia
whether
patient
need
blood
transfus
ultim
clinic
decis
emerg
transfus
lifesav
patient
anaemia
develop
quickli
allow
physiolog
compens
sever
malariarel
anaemia
children
sudden
sever
obstetr
bleed
contrast
anaemia
develop
slowli
exampl
due
hookworm
infest
nutrit
defici
patient
gener
manag
conserv
treat
caus
anaemia
prescrib
haematin
replac
iron
supplement
continu
least
month
haemoglobin
return
normal
bodi
store
replenish
clinic
guidelin
possibl
avoid
unnecessari
transfus
adher
clinic
transfus
guidelin
institut
develop
guidelin
help
clinician
make
ration
decis
use
blood
transfus
box
strict
enforc
transfus
protocol
significantli
reduc
avoid
transfus
principl
underli
transfus
guidelin
similar
combin
clinic
assess
oxygen
haemoglobin
measur
use
surrog
measur
intracellular
oxygen
concentr
increasingli
transfus
guidelin
make
use
evid
show
adequ
oxygen
deliveri
tissu
achiev
haemoglobin
level
significantli
lower
normal
rang
implement
transfus
guidelin
particularli
difficult
clinician
access
reliabl
haemoglobin
highrisk
donor
commerci
sex
worker
contact
intraven
drug
abus
itiner
lifestyl
trader
driver
militari
personnel
deter
donat
even
area
hiv
infect
rate
gener
popul
high
donor
deferr
effect
exclud
hivinfect
donor
whole
donat
process
includ
test
hiv
infect
explain
donor
blood
collect
donor
option
know
result
receiv
counsel
imper
complet
confidenti
maintain
throughout
procedur
infect
organ
hiv
hepat
virus
cytomegaloviru
syphili
lyme
borreliosi
malaria
babesiosi
american
trypanosomiasi
chaga
diseas
toxoplasmosi
acquir
blood
transfus
hiv
infect
worldwid
thought
transmit
transfus
infect
blood
blood
product
also
report
transmiss
variant
creutzfeldtjakob
diseas
blood
transfus
theoret
risk
transmiss
sever
acut
respiratori
syndrom
sar
recommend
donat
blood
screen
hiv
hepat
b
syphili
feasibl
appropri
hepat
c
malaria
chaga
diseas
malaria
transmit
blood
transfus
depend
local
infect
preval
blood
donor
africa
screen
posit
malaria
howev
littl
evid
suggest
donor
transmit
malaria
transfus
recipi
although
recommend
screen
donor
endem
area
malaria
none
screen
method
would
practic
transfus
servic
suffici
sensit
furthermor
countri
high
malaria
transmiss
exclus
parasitaem
donor
could
result
deferr
rate
exceed
would
major
impact
blood
suppli
evid
support
widespread
practic
routin
treatment
transfus
recipi
malaria
fresh
blood
potenti
infecti
syphili
storag
day
inactiv
treponema
pallidum
high
demand
blood
lowincom
countri
mean
blood
gener
store
long
enough
inactiv
pallidum
syphili
seroconvers
associ
transfus
report
africa
global
preval
hepat
c
chaga
diseas
variabl
decis
introduc
donor
screen
infect
base
local
assess
risk
benefit
feasibl
cost
blood
separ
compon
residu
risk
infect
high
increas
number
potenti
infect
recipi
unit
blood
usual
store
screen
test
infect
complet
mean
potenti
infect
blood
may
mix
unit
alreadi
screen
costli
blood
collect
bag
wast
screen
potenti
donor
venesect
unit
blood
may
therefor
costeffect
way
ensur
safe
blood
test
screen
blood
donor
need
highli
sensit
infect
blood
reject
inform
donor
outcom
posit
result
confirm
use
test
high
degre
specif
blood
blood
may
becom
infect
bacteria
process
intraop
blood
salvag
involv
collect
blood
lost
oper
reinfus
patient
either
surgeri
although
techniqu
practic
safe
reduc
need
donor
blood
requir
special
equip
train
may
expens
routin
donat
blood
measur
normal
salin
intraven
replac
fluid
use
judici
acut
blood
loss
certain
circumst
may
effect
whole
blood
red
cell
plasma
erythropoietin
stimul
endogen
red
cell
product
wellestablish
use
chronic
anaemia
due
renal
failur
cancer
hiv
infect
delay
action
make
unsuit
use
acut
anaemia
synthet
oxygen
carrier
perfluorocarbon
yet
routin
avail
lowincom
countri
recommend
haemoglobin
threshold
transfus
often
well
would
accept
wealthi
countri
random
control
studi
wealthi
countri
indic
adult
children
undergo
critic
care
haemoglobin
threshold
gl
transfus
safe
wherea
paediatr
blood
transfus
protocol
subsaharan
africa
often
recommend
transfus
stabl
children
haemoglobin
level
less
gl
complic
cardiac
failur
infect
may
necessit
transfus
higher
haemoglobin
level
transfus
combin
adequ
haematin
replac
underli
condit
treat
earli
evid
suggest
intermitt
prevent
treatment
antimalari
may
reduc
high
hospit
readmiss
rate
experienc
children
posttransfus
complic
occur
immedi
transfus
within
hour
complet
delay
mani
year
case
viral
infect
box
measur
doubt
haemoglobin
result
clinician
reli
entir
clinic
judgement
guid
transfus
practic
lead
signific
number
inappropri
transfus
lack
invest
qualiti
critic
test
haemoglobin
measur
wast
signific
resourc
downstream
transfus
process
unnecessarili
expos
recipi
risk
transfusionrel
infect
minim
surgic
blood
loss
blood
short
suppli
particularli
import
ensur
best
anaesthet
surgic
techniqu
use
minim
blood
loss
surgeri
drug
improv
haemostasi
reduc
fibrinolysi
aprotinin
cyklokapron
fibrin
sealant
effect
reduc
periop
blood
loss
drug
therefor
reduc
need
blood
transfus
may
expens
use
lowincom
countri
costeffect
studi
surgic
bleed
four
subsaharan
countri
indic
antifibrinolyt
tranexam
acid
could
save
live
countri
blood
shortag
reduc
healthcar
cost
prevent
transmiss
infect
preoper
autolog
blood
deposit
patient
undergo
plan
surgeri
like
requir
blood
transfus
unit
blood
remov
store
case
signific
intraop
blood
loss
need
transfus
process
known
preoper
autolog
donat
reduc
need
allogen
transfus
requir
care
organ
surgeon
need
predict
much
blood
requir
patient
fit
enough
withstand
remov
one
unit
blood
week
preced
surgeri
surgeri
must
take
place
within
shelflif
blood
blood
store
blood
bank
still
risk
patient
may
receiv
blood
box
prescrib
blood
checklist
clinician
alway
ask
follow
question
prescrib
blood
blood
product
patient
improv
patient
clinic
condit
aim
achiev
minim
blood
loss
reduc
patient
need
transfus
treatment
give
make
decis
transfus
intraven
replac
fluid
oxygen
specif
clinic
laboratori
indic
transfus
patient
risk
transmit
hiv
hepat
syphili
infecti
agent
blood
product
avail
patient
bacteri
contamin
investig
manag
accordingli
allerg
reaction
due
infus
plasma
protein
manifest
includ
erythema
rash
pruritu
bronchospasm
anaphylaxi
transfus
stop
patient
treat
antihistamin
reaction
mild
symptom
sign
complet
disappear
transfus
restart
type
mild
reaction
occur
repeatedli
one
unit
blood
red
cell
wash
transfus
done
absolut
necessari
carri
risk
introduc
potenti
fatal
bacteri
infect
sever
allerg
reaction
evid
system
toxic
manag
acut
anaphylaxi
blood
alway
transfus
slowli
avoid
overload
circul
unless
patient
activ
sever
bleed
fluid
overload
may
particular
problem
paediatr
blood
bag
avail
children
may
overtransfus
due
miscalcul
requir
volum
lack
accur
infus
devic
inadvert
administr
adults
unit
blood
four
unit
blood
contain
equival
amount
iron
store
bone
marrow
approx
g
repeat
transfus
chronic
haemolyt
anaemia
thalassaemia
major
sickl
cell
diseas
lead
iron
deposit
parenchym
cell
eventu
failur
heart
liver
organ
supersed
adequ
dose
iron
chelat
inject
desferrioxamin
oral
deferipron
abl
maintain
accept
iron
balanc
patient
chronic
anaemia
need
regular
transfus
usual
necessari
warm
blood
unless
larg
quantiti
transfus
rapidli
may
lower
temperatur
sinoatri
node
point
ventricular
fibril
occur
blood
need
warm
electr
blood
warmer
specif
design
purpos
use
keep
temperatur
avoid
haemolysi
associ
overh
blood
graftversushost
diseas
occur
donor
lymphocyt
engraft
immunesuppress
recipi
lymphocyt
recogn
recipi
bone
marrow
foreign
induc
aplasia
graftversushost
diseas
almost
univers
fatal
prevent
irradi
donor
blood
inactiv
donor
lymphocyt
transfus
blood
recipi
possess
antibodi
donor
red
cell
caus
acut
occasion
fatal
intravascular
haemolysi
could
occur
eg
group
cell
transfus
group
recipi
natur
occur
antibodi
group
cell
profound
haemolysi
induc
renal
vasoconstrict
acut
tubular
necrosi
treatment
involv
stop
transfus
cardiorespiratori
support
induc
brisk
diuresi
addit
abnorm
indic
renal
failur
laboratori
find
includ
haemoglobinuria
haemoglobinaemia
proof
diagnosi
involv
recheck
whole
transfus
process
includ
document
stage
regroup
donor
recipi
screen
antibodi
red
cell
direct
antiglobulin
test
test
usual
avail
hospit
laboratori
capabl
provid
transfus
servic
delay
haemolysi
similar
physiolog
basi
acut
intravascular
haemolysi
tend
less
sever
occur
day
transfus
less
like
present
clinic
emerg
limit
data
subsaharan
africa
show
rate
bacteri
contamin
donat
blood
around
clinic
consequ
transfus
recipi
unknown
bacteria
enter
blood
bag
venesect
bag
breach
eg
reduc
volum
paediatr
recipi
compon
prepar
gramneg
bacteria
includ
pseudomona
yersinia
grow
optim
infect
blood
may
necessarili
appear
abnorm
nake
eye
reaction
follow
infus
infect
blood
often
due
endotoxin
may
occur
sever
hour
transfus
finish
although
reaction
rare
sever
fatal
bacteri
contamin
suspect
transfus
stop
sampl
patient
blood
bag
sent
laboratori
cultur
cardiorespiratori
support
may
need
broadspectrum
antibiot
start
immedi
continu
cultur
result
avail
nonhaemolyt
febril
reaction
episod
fever
chill
associ
transfus
caus
found
due
recipi
antibodi
react
antigen
present
donor
white
cell
platelet
reaction
common
patient
transfus
past
therefor
expos
alloantigen
mild
febril
reaction
usual
respond
simpl
antipyret
paracetamol
sever
reaction
may
first
indic
haemolyt
transfus
reaction
